edaravone has been researched along with Disease Models, Animal in 163 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study aimed to investigate the influences of edaravone on necroptosis-related proteins and oxidative stress in rats with lower extremity ischemia/reperfusion (I/R) injury." | 8.12 | Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury. ( Hu, Z; Li, Y; Wang, L; Zhao, G; Zhao, L, 2022) |
| "Our previous studies confirm that exogenous reduced nicotinamide adenine dinucleotide phosphate (NADPH) exerts a neuroprotective effect in animal models of ischemic stroke, and its primary mechanism is related to anti-oxidative stress and improved energy metabolism." | 8.12 | NADPH is superior to NADH or edaravone in ameliorating metabolic disturbance and brain injury in ischemic stroke. ( Chen, Z; Han, R; Li, M; Mao, GH; Qin, ZH; She, J; Sheng, R; Wang, F; Wang, XX; Wu, JC; Zhang, R, 2022) |
| " Edaravone is a powerful free radical scavenger used for the treatment of ischemia/reperfusion diseases due to its anti-oxidative stress and anti-inflammatory properties." | 8.02 | Effect of edaravone on pregnant mice and their developing fetuses subjected to placental ischemia. ( Abe, K; Atallah, M; Yamashita, T, 2021) |
| "This study was conducted to explore whether the effect of edaravone (5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol3-one, EDR) can ameliorate renal warm ischemia-reperfusion injury (IRI) by modulating endoplasmic reticulum stress (ERS) and its downstream effector after cardiac arrest (CA) and cardiopulmonary resuscitation (CPR) in a rat model." | 7.96 | Edaravone Ameliorates Renal Warm Ischemia-Reperfusion Injury by Downregulating Endoplasmic Reticulum Stress in a Rat Resuscitation Model. ( Chen, MH; Fu, ZY; Li, N; Lu, JY; Wu, ZJ; Zheng, JH, 2020) |
| "Mild hypothermia (MH) and edaravone (EDA) exert neuroprotective effects against cerebral ischemia/reperfusion (I/R) injury through activation of the nuclear factor erythroid 2‑related factor 2 (Nrf2) pathway." | 7.96 | Protective effects of combined treatment with mild hypothermia and edaravone against cerebral ischemia/reperfusion injury via oxidative stress and Nrf2 pathway regulation. ( Dai, M; Gao, C; Kang, F; Liu, R; Wang, X; Wu, Z; Yu, H, 2020) |
| "The effects of edaravone against pentylenetetrazole (PTZ)-induced epilepsy in male albino rats were investigated." | 7.91 | Edaravone acts as a potential therapeutic drug against pentylenetetrazole-induced epilepsy in male albino rats by downregulating cyclooxygenase-II. ( Liu, LM; Lu, Y; Wang, N; Wang, WP, 2019) |
| "Amitriptyline (AMT) cardiotoxicity is commonly seen with high morbidity and mortality rates in emergency departments." | 7.91 | Beneficial effects of edaravone in experimental model of amitriptyline-induced cardiotoxicity in rats. ( Aygun, H; Basol, N; Gul, SS, 2019) |
| "Edaravone ameliorated ONI-induced ROS production, RGC death, and inner retinal degeneration." | 7.85 | Edaravone Prevents Retinal Degeneration in Adult Mice Following Optic Nerve Injury. ( Akiyama, G; Azuchi, Y; Guo, X; Harada, C; Harada, T; Kimura, A; Namekata, K; Noro, T, 2017) |
| "To explore the effect of edaravone on bone marrow mesenchymal stem cells (BMSCs) transplanted to treat acute myocardial infarction (AMI) and the underlying mechanism." | 7.83 | Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model. ( Gu, TX; Li-Ling, J; Qi, X; Sun, XJ; Wang, C; Wang, XB; Zhang, GW, 2016) |
| "Edaravone is widely used for treating ischemic stroke, but it is not still confirmed in intracerebral hemorrhage (ICH) as an ideal medication targeting the brain parenchyma." | 7.83 | Stereotactic Administration of Edaravone Ameliorates Collagenase-Induced Intracerebral Hemorrhage in Rat. ( Gao, M; Ge, GZ; Ji, XC; Sun, YL; Wang, QQ; Xu, RX; Yang, Y; Zhang, GZ; Zhang, HT; Zhang, Y, 2016) |
| "The present study was designed to evaluate the cardioprotective potential of edaravone on oxidative stress, anti-apoptotic, anti-inflammatory and ultrastructure findings in isoproterenol (ISO) induced myocardial infarction (MI) in rats." | 7.81 | Edaravone protects rats against oxidative stress and apoptosis in experimentally induced myocardial infarction: Biochemical and ultrastructural evidence. ( Akhtar, M; Akhtar, MS; Ali, J; Haque, SE; Hassan, MQ; Najmi, AK, 2015) |
| " The free-radical scavenger edaravone is used in combination with the recombinant tissue plasminogen activator alteplase to treat acute ischemic stroke." | 7.81 | The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model. ( Ishii, H; Sakamoto, K; Sato, T; Yamamoto, J; Yamashita, T, 2015) |
| "In present study, we evaluated acute neuroprotective effects of combined therapy with pharmacologically induced hypothermia and edaravone in a rat model of intracerebral hemorrhage (ICH)." | 7.81 | Early Combined Therapy with Pharmacologically Induced Hypothermia and Edaravone Exerts Neuroprotective Effects in a Rat Model of Intracerebral Hemorrhage. ( Liu, C; Sun, Z; Zhu, Y, 2015) |
| "Edaravone, a potent antioxidant, may improve thrombolytic therapy because it benefits ischemic stroke patients on its own and mitigates adverse effects of tissue plasminogen activator (tPA) in preclinical models." | 7.80 | Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke. ( Abe, K; Chan, PH; Dunn, RS; Kuan, CY; Li, Y; Lindquist, DM; Morozov, YM; Rakic, P; Sun, YY; Yang, D, 2014) |
| "Edaravone is a novel free radical scavenger that is clinically employed in patients with acute cerebral infarction." | 7.78 | Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury. ( Chen, X; Gao, M; Lei, S; Li, L; Li, W; Li, X; Liu, Y; Lu, H; Wang, N; Zhang, P; Zheng, J, 2012) |
| "To investigate whether edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a free radical scavenger, would be neuroprotective against photoreceptor cell death in a rat model of retinal detachment (RD)." | 7.77 | Edaravone, an ROS scavenger, ameliorates photoreceptor cell death after experimental retinal detachment. ( Miller, JW; Murakami, Y; Roh, MI; Thanos, A; Vavvas, DG, 2011) |
| " The aim of this study was to examine the effect of edaravone, a free radical scavenger, on the development of fibrosis and autoimmunity in two different mouse models of SSc." | 7.77 | The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. ( Asano, Y; Iwata, Y; Kadono, T; Ogawa, A; Ogawa, F; Sato, S; Shimizu, K; Takenaka, M; Yanaba, K; Yoshizaki, A, 2011) |
| "To increase the survival rate of patients with acute superior mesenteric artery thromboembolism (ASMAT) treated by catheter thrombolysis, we examined the effects of delivering edaravone and asialoerythropoietin, agents with tissue-protective activities, using a rabbit autologous fibrin clot ASMAT model." | 7.76 | Does the concomitant intra-arterial injection of asialoerythropoietin and edaravone mitigate ischaemic mucosal damage after acute superior mesenteric artery thromboembolism in a rabbit autologous fibrin clot model? ( Kashiwagi, A; Murata, K; Nitta, N; Ohta, S; Seko, A; Sonoda, A; Sugimoto, T; Takahashi, M; Takemura, S; Uzu, T; Yokomaku, Y, 2010) |
| "To compare the protective effect of nerve growth factor (NGF) and edaravone (a free radical scavenger) pretreatment against cerebral ischemia/reperfusion (I/R) injury to nerve cells." | 7.76 | [A comparative study on the protection effect of nerve growth factor and edaravone pretreatment against cerebral ischemia/reperfusion injury]. ( Fu, JQ; Liu, H; Wang, DF, 2010) |
| "The aim of this study was to evaluate the effects of intra-arterial administration of edaravone after superior mesenteric artery (SMA) thromboembolism in a rabbit model." | 7.75 | Edaravone prevents bowel infarction after acute superior mesenteric artery thromboembolism using autologous fibrin clots in a rabbit model. ( Miyagawa, Y; Murata, K; Nitta, N; Ohta, S; Seko, A; Sonoda, A; Takahashi, M; Takemura, S, 2009) |
| "Our aim in this study was to find out whether edaravone (3-methyl-1-phenyl-pyrazolin-5-one, MCI-186), a novel free radical scavenger, improved the survival rate in a rat hemorrhagic shock (HS) model." | 7.74 | Edaravone improves the survival of rats subjected to hemorrhagic shock without resuscitation. ( Akabori, H; Endo, Y; Mori, T; Shimizu, T; Tani, T; Tsuchihashi, H; Uji, Y; Yamamoto, H, 2008) |
| "Effects of potent free radical scavenger, edaravone, on oxidative stress-induced endothelial damage and early atherosclerosis were investigated using animal models and cultured cells." | 7.74 | Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis. ( Akishita, M; Eto, M; Hasegawa, H; Kozaki, K; Nagai, K; Toba, K; Xi, H; Yu, W, 2007) |
| "Prophylactic administration of edaravone exerted a significant protective effect against postoperative neurologic dysfunction after antegrade selective cerebral perfusion in a canine model with old cerebral infarction." | 7.74 | Effect of prophylactically administered edaravone during antegrade cerebral perfusion in a canine model of old cerebral infarction. ( Akuzawa, S; Bashar, AH; Fujie, M; Kazui, T; Ohishi, K; Ohkura, K; Suzuki, K; Suzuki, T; Terada, H; Washiyama, N; Yamamoto, S; Yamashita, K, 2007) |
| "To analyse the protective effect of a free radical scavenger, edaravone, on endolymphatic hydrops." | 7.74 | Protective effect of edaravone against endolymphatic hydrops. ( Anniko, M; Kakigi, A; Nakatani, H; Takeda, S; Takeda, T; Takumida, M, 2007) |
| " In the first, the dose-dependent effects of edaravone on ICH-induced brain injury were examined by measuring brain edema and neurologic deficits." | 7.74 | Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. ( Itano, T; Keep, RF; Kuroda, Y; Miyamoto, O; Nagao, S; Nakamura, T; Tamiya, T; Xi, G; Yamashita, S; Zhang, X, 2008) |
| "Intrathecally administered edaravone, a free radical scavenger, had analgesic effects on inflammatory-induced acute and facilitated pain but not on acute thermal pain, without any behavioural side-effects." | 7.73 | Intrathecal edaravone, a free radical scavenger, is effective on inflammatory-induced pain in rats. ( Nishiyama, T; Ogawa, M, 2005) |
| " The present study was undertaken to examine whether or not the free radical scavenger, edaravone, could prevent the extravasation of tPA administered for the purpose of fibrinolysis in a rat model of thromboembolic stroke." | 7.73 | Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. ( Harada, T; Kano, T; Katayama, Y, 2005) |
| "Compared to vehicle group, IR significantly decreased the PO(2) level and increased the wet-to-dry ratio, proteins in bronchoalveolar lavage (BAL), and myeloperoxidase (MPO) activity in the control group, while edaravone treatment maintained the PO(2) similar to the vehicle group and significantly reduced edema formation and neutrophil extravasation." | 7.73 | MCI-186 (edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A(2) in an isolated rat lung model after 18 h of cold preservation. ( Akamatsu, H; Reyes, YA; Shimoyama, T; Sunamori, M, 2006) |
| " In the present investigation, we examined the effects of the radical scavenger edaravone administered at various time points to rats with puromycin nephrosis." | 7.73 | Protective effect of radical scavenger edaravone against puromycin nephrosis. ( Ashida, A; Hirano, K; Matsumura, H; Nakakura, H; Tamai, H, 2006) |
| " This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures." | 6.61 | Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. ( Jaiswal, MK, 2019) |
| "Edaravone is a promising treatment for stroke." | 6.50 | Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review. ( Egan, K; Macleod, M; Mead, G; Sena, E; Wu, S, 2014) |
| "Among all the treatments for Multiple Sclerosis, stem cell transplantation, such as ADSCs, has attracted a great deal of scientific attention." | 5.62 | Evaluation of Edaravone effects on the differentiation of human adipose derived stem cells into oligodendrocyte cells in multiple sclerosis disease in rats. ( Amirpour, N; Bakhtiari, M; Ghasemi, N; Kazemi, M; Mardani, M; Salehi, H, 2021) |
| "Edaravone has showed its neuroprotective effects after ischemia stroke, but its effects and possible mechanisms after ICH are poorly understood." | 5.56 | Edaravone Administration Confers Neuroprotection after Experimental Intracerebral Hemorrhage in Rats via NLRP3 Suppression. ( Geng, J; Jiang, Y; Miao, H; Tang, J; Zhang, B; Zhu, G, 2020) |
| "Edaravone (3 mg/kg) was administered intravenously to 14 C57BL/6 mice just before reperfusion." | 5.56 | Effects of Edaravone on Nitric Oxide, Hydroxyl Radicals and Neuronal Nitric Oxide Synthase During Cerebral Ischemia and Reperfusion in Mice. ( Araki, N; Hirayama, M; Ishizawa, K; Ito, Y; Kawasaki, H; Kitabayashi, C; Nagai, T; Nishioka, R; Takahashi, K; Tanaka, A; Yamamoto, T; Yamazato, M, 2020) |
| "Edaravone (Edv) can inhibit tissue damage, cause cerebral edema, and delay neuronal death caused by acute cerebral infarction." | 5.56 | Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke. ( Li, F; Liang, J; Shi, Y; Zhao, L, 2020) |
| "Edaravone is a free radical scavenger, and borneol has shown anti-inflammatory effect." | 5.40 | The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. ( Gao, LY; Hua, Y; Liao, GY; Luo, CX; Sun, WX; Tang, Y; Wu, HY; Yang, SB; Zhang, ZP; Zhou, QG; Zhu, DY, 2014) |
| "Edaravone treatment significantly reduced messenger RNA expressions of cytokines and matrix metalloproteinases (MMPs) in aneurysm walls (MMP-2: 1." | 5.38 | Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats. ( Hasegawa, T; Morimoto, K; Morimoto, N; Okada, K; Okita, Y; Tanaka, A; Wulan, B; Yu, J, 2012) |
| "The degree of cerebral vasospasm was evaluated by measuring the diameter of each basilar artery, and the expression of Rho-kinase in the vascular wall was examined by western blotting." | 5.37 | Effect of a free radical scavenger, edaravone, on free radical reactions: related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model. ( Munakata, A; Ohkuma, H; Shimamura, N, 2011) |
| "Edaravone treatment significantly reduced the elevated malondialdehyde levels in rat lungs after acute pancreatitis, suggesting an important role for free radicals in acute pancreatitis-associated lung injury." | 5.36 | Protective effects of the free radical scavenger edaravone on acute pancreatitis-associated lung injury. ( Cai, ZY; Deng, XM; Hou, J; Hu, JY; Liu, SQ; Mao, YF; Ni, X; Yang, T; Zhu, XY, 2010) |
| "Edaravone (MCI-186) is a newly developed antioxidative radical scavenger for the treatment of acute cerebral infarction, exerting neuroprotective effects against ischemic insult." | 5.35 | Neuroprotective effects of edaravone, a free radical scavenger, on the rat hippocampus after pilocarpine-induced status epilepticus. ( Abe, T; Anan, M; Fujiki, M; Kamida, T; Kobayashi, H; Ooba, H, 2009) |
| "Edaravone is a lipophilic drug with multiple mechanisms of action." | 5.35 | The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. ( Lapchak, PA; Zivin, JA, 2009) |
| "Edaravone treatment shifted the %FAC(initial)–%FAC(final) relationship downward (P < 0." | 5.35 | Development of cardiac dysfunction induced by repetitive transient myocardial ischemia is inhibited by edaravone in conscious rats. ( Imai, K; Kawamoto, T; Miyamoto, Y; Neishi, Y; Okura, H; Toyota, E; Yoshida, K, 2009) |
| "Edaravone (10 mg/kg) was delivered intravenously before ischemia and after reperfusion to prevent the neutrophil activation." | 5.33 | Treatment with edaravone improves the survival rate in renal warm ischemia-reperfusion injury using rat model. ( Funao, K; Hayama, T; Kawahito, Y; Matsuyama, M; Nakatani, T; Sano, H; Sugimura, K; Takemoto, Y; Tsuchida, K; Yoshimura, R, 2006) |
| "The study aimed to investigate the influences of edaravone on necroptosis-related proteins and oxidative stress in rats with lower extremity ischemia/reperfusion (I/R) injury." | 4.12 | Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury. ( Hu, Z; Li, Y; Wang, L; Zhao, G; Zhao, L, 2022) |
| "Our previous studies confirm that exogenous reduced nicotinamide adenine dinucleotide phosphate (NADPH) exerts a neuroprotective effect in animal models of ischemic stroke, and its primary mechanism is related to anti-oxidative stress and improved energy metabolism." | 4.12 | NADPH is superior to NADH or edaravone in ameliorating metabolic disturbance and brain injury in ischemic stroke. ( Chen, Z; Han, R; Li, M; Mao, GH; Qin, ZH; She, J; Sheng, R; Wang, F; Wang, XX; Wu, JC; Zhang, R, 2022) |
| "DL‑3‑n‑butylphthalide (NBP) and 3‑methyl‑1- phenyl‑2‑pyrazolin‑5‑one (edaravone) are acknowledged neuroprotective agents that protect against ischemic stroke." | 4.02 | Protective multi‑target effects of DL‑3‑n‑butylphthalide combined with 3‑methyl‑1‑phenyl‑2‑pyrazolin‑5‑one in mice with ischemic stroke. ( Cheng, Y; Guan, Y; Guo, L; Li, P; Liu, Y; Wu, Q, 2021) |
| " Edaravone is a powerful free radical scavenger used for the treatment of ischemia/reperfusion diseases due to its anti-oxidative stress and anti-inflammatory properties." | 4.02 | Effect of edaravone on pregnant mice and their developing fetuses subjected to placental ischemia. ( Abe, K; Atallah, M; Yamashita, T, 2021) |
| "This study was conducted to explore whether the effect of edaravone (5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol3-one, EDR) can ameliorate renal warm ischemia-reperfusion injury (IRI) by modulating endoplasmic reticulum stress (ERS) and its downstream effector after cardiac arrest (CA) and cardiopulmonary resuscitation (CPR) in a rat model." | 3.96 | Edaravone Ameliorates Renal Warm Ischemia-Reperfusion Injury by Downregulating Endoplasmic Reticulum Stress in a Rat Resuscitation Model. ( Chen, MH; Fu, ZY; Li, N; Lu, JY; Wu, ZJ; Zheng, JH, 2020) |
| "Mild hypothermia (MH) and edaravone (EDA) exert neuroprotective effects against cerebral ischemia/reperfusion (I/R) injury through activation of the nuclear factor erythroid 2‑related factor 2 (Nrf2) pathway." | 3.96 | Protective effects of combined treatment with mild hypothermia and edaravone against cerebral ischemia/reperfusion injury via oxidative stress and Nrf2 pathway regulation. ( Dai, M; Gao, C; Kang, F; Liu, R; Wang, X; Wu, Z; Yu, H, 2020) |
| "The effects of edaravone against pentylenetetrazole (PTZ)-induced epilepsy in male albino rats were investigated." | 3.91 | Edaravone acts as a potential therapeutic drug against pentylenetetrazole-induced epilepsy in male albino rats by downregulating cyclooxygenase-II. ( Liu, LM; Lu, Y; Wang, N; Wang, WP, 2019) |
| "Amitriptyline (AMT) cardiotoxicity is commonly seen with high morbidity and mortality rates in emergency departments." | 3.91 | Beneficial effects of edaravone in experimental model of amitriptyline-induced cardiotoxicity in rats. ( Aygun, H; Basol, N; Gul, SS, 2019) |
| "Edaravone ameliorated ONI-induced ROS production, RGC death, and inner retinal degeneration." | 3.85 | Edaravone Prevents Retinal Degeneration in Adult Mice Following Optic Nerve Injury. ( Akiyama, G; Azuchi, Y; Guo, X; Harada, C; Harada, T; Kimura, A; Namekata, K; Noro, T, 2017) |
| " In the present study we've examined the effect of a free radical scavenger, edaravone pretreatment against LPS-induced anxiety and depressive-like behavior as well as various hippocampal biochemical parameters including PARP-1." | 3.83 | Edaravone abrogates LPS-induced behavioral anomalies, neuroinflammation and PARP-1. ( Bezbaruah, BK; Gurjar, SS; Jangra, A; Mohan, P; Sriram, CS, 2016) |
| "To explore the effect of edaravone on bone marrow mesenchymal stem cells (BMSCs) transplanted to treat acute myocardial infarction (AMI) and the underlying mechanism." | 3.83 | Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model. ( Gu, TX; Li-Ling, J; Qi, X; Sun, XJ; Wang, C; Wang, XB; Zhang, GW, 2016) |
| "Edaravone is widely used for treating ischemic stroke, but it is not still confirmed in intracerebral hemorrhage (ICH) as an ideal medication targeting the brain parenchyma." | 3.83 | Stereotactic Administration of Edaravone Ameliorates Collagenase-Induced Intracerebral Hemorrhage in Rat. ( Gao, M; Ge, GZ; Ji, XC; Sun, YL; Wang, QQ; Xu, RX; Yang, Y; Zhang, GZ; Zhang, HT; Zhang, Y, 2016) |
| "Compound IMM-H004 (7-hydroxy-5-methoxy-4-methyl-3-[4-methylpiperazin-1-yl]-2H-chromen-2-one) is a new synthetic derivative of coumarin, and previous studies showed that it exhibited antioxidant and neuroprotective roles in focal cerebral ischemia." | 3.81 | Compound IMM-H004, a novel coumarin derivative, protects against CA1 cell loss and spatial learning impairments resulting from transient global ischemia. ( Chen, NH; Han, N; Zhang, W; Zuo, W, 2015) |
| "The present study was designed to evaluate the cardioprotective potential of edaravone on oxidative stress, anti-apoptotic, anti-inflammatory and ultrastructure findings in isoproterenol (ISO) induced myocardial infarction (MI) in rats." | 3.81 | Edaravone protects rats against oxidative stress and apoptosis in experimentally induced myocardial infarction: Biochemical and ultrastructural evidence. ( Akhtar, M; Akhtar, MS; Ali, J; Haque, SE; Hassan, MQ; Najmi, AK, 2015) |
| " The free-radical scavenger edaravone is used in combination with the recombinant tissue plasminogen activator alteplase to treat acute ischemic stroke." | 3.81 | The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model. ( Ishii, H; Sakamoto, K; Sato, T; Yamamoto, J; Yamashita, T, 2015) |
| "In present study, we evaluated acute neuroprotective effects of combined therapy with pharmacologically induced hypothermia and edaravone in a rat model of intracerebral hemorrhage (ICH)." | 3.81 | Early Combined Therapy with Pharmacologically Induced Hypothermia and Edaravone Exerts Neuroprotective Effects in a Rat Model of Intracerebral Hemorrhage. ( Liu, C; Sun, Z; Zhu, Y, 2015) |
| "Edaravone, a potent antioxidant, may improve thrombolytic therapy because it benefits ischemic stroke patients on its own and mitigates adverse effects of tissue plasminogen activator (tPA) in preclinical models." | 3.80 | Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke. ( Abe, K; Chan, PH; Dunn, RS; Kuan, CY; Li, Y; Lindquist, DM; Morozov, YM; Rakic, P; Sun, YY; Yang, D, 2014) |
| " The incidence of facial palsy was assessed following administration of edaravone immediately after HSV-1 inoculation and daily for 11 days thereafter." | 3.79 | Role of nitric oxide in the onset of facial nerve palsy by HSV-1 infection. ( Gyo, K; Hato, N; Kohno, H; Takahashi, H; Yamada, H, 2013) |
| "Edaravone is a novel free radical scavenger that is clinically employed in patients with acute cerebral infarction." | 3.78 | Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury. ( Chen, X; Gao, M; Lei, S; Li, L; Li, W; Li, X; Liu, Y; Lu, H; Wang, N; Zhang, P; Zheng, J, 2012) |
| "We evaluated a battery of functional tests for investigating the effects of edaravone, a free radical scavenger, in SOD1 transgenic (H46R) rat model of amyotrophic lateral sclerosis." | 3.77 | Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. ( Aoki, M; Itoyama, Y; Mizuno, H; Suzuki, N; Warita, H; Yuki, S, 2011) |
| "To investigate whether edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a free radical scavenger, would be neuroprotective against photoreceptor cell death in a rat model of retinal detachment (RD)." | 3.77 | Edaravone, an ROS scavenger, ameliorates photoreceptor cell death after experimental retinal detachment. ( Miller, JW; Murakami, Y; Roh, MI; Thanos, A; Vavvas, DG, 2011) |
| " The aim of this study was to examine the effect of edaravone, a free radical scavenger, on the development of fibrosis and autoimmunity in two different mouse models of SSc." | 3.77 | The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. ( Asano, Y; Iwata, Y; Kadono, T; Ogawa, A; Ogawa, F; Sato, S; Shimizu, K; Takenaka, M; Yanaba, K; Yoshizaki, A, 2011) |
| "In a rabbit model with aortic clamping up to 30 minutes, which consistently produces complete paraplegia in rabbits, spinal cord damage was partially reduced by topical cooling with transvertebral cooling pads or the injection of edaravone into the clamped segment of aorta, but was more effectively protected by a combined use of these two strategies." | 3.77 | New method for absolute spinal cord ischemia protection in rabbits. ( Herlambang, B; Hiyama, E; Mizukami, T; Orihashi, K; Sueda, T; Takahashi, S; Uchida, N, 2011) |
| "To increase the survival rate of patients with acute superior mesenteric artery thromboembolism (ASMAT) treated by catheter thrombolysis, we examined the effects of delivering edaravone and asialoerythropoietin, agents with tissue-protective activities, using a rabbit autologous fibrin clot ASMAT model." | 3.76 | Does the concomitant intra-arterial injection of asialoerythropoietin and edaravone mitigate ischaemic mucosal damage after acute superior mesenteric artery thromboembolism in a rabbit autologous fibrin clot model? ( Kashiwagi, A; Murata, K; Nitta, N; Ohta, S; Seko, A; Sonoda, A; Sugimoto, T; Takahashi, M; Takemura, S; Uzu, T; Yokomaku, Y, 2010) |
| "To compare the protective effect of nerve growth factor (NGF) and edaravone (a free radical scavenger) pretreatment against cerebral ischemia/reperfusion (I/R) injury to nerve cells." | 3.76 | [A comparative study on the protection effect of nerve growth factor and edaravone pretreatment against cerebral ischemia/reperfusion injury]. ( Fu, JQ; Liu, H; Wang, DF, 2010) |
| "The aim of this study was to evaluate the effects of intra-arterial administration of edaravone after superior mesenteric artery (SMA) thromboembolism in a rabbit model." | 3.75 | Edaravone prevents bowel infarction after acute superior mesenteric artery thromboembolism using autologous fibrin clots in a rabbit model. ( Miyagawa, Y; Murata, K; Nitta, N; Ohta, S; Seko, A; Sonoda, A; Takahashi, M; Takemura, S, 2009) |
| "Our aim in this study was to find out whether edaravone (3-methyl-1-phenyl-pyrazolin-5-one, MCI-186), a novel free radical scavenger, improved the survival rate in a rat hemorrhagic shock (HS) model." | 3.74 | Edaravone improves the survival of rats subjected to hemorrhagic shock without resuscitation. ( Akabori, H; Endo, Y; Mori, T; Shimizu, T; Tani, T; Tsuchihashi, H; Uji, Y; Yamamoto, H, 2008) |
| "Effects of potent free radical scavenger, edaravone, on oxidative stress-induced endothelial damage and early atherosclerosis were investigated using animal models and cultured cells." | 3.74 | Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis. ( Akishita, M; Eto, M; Hasegawa, H; Kozaki, K; Nagai, K; Toba, K; Xi, H; Yu, W, 2007) |
| "Prophylactic administration of edaravone exerted a significant protective effect against postoperative neurologic dysfunction after antegrade selective cerebral perfusion in a canine model with old cerebral infarction." | 3.74 | Effect of prophylactically administered edaravone during antegrade cerebral perfusion in a canine model of old cerebral infarction. ( Akuzawa, S; Bashar, AH; Fujie, M; Kazui, T; Ohishi, K; Ohkura, K; Suzuki, K; Suzuki, T; Terada, H; Washiyama, N; Yamamoto, S; Yamashita, K, 2007) |
| "Rats receiving intracolonic administration of indomethacin develop longitudinal ulcers on the mesenteric side of the small intestine that are similar to those seen in the acute phase of Crohn's disease." | 3.74 | Microcirculatory changes in experimental mesenteric longitudinal ulcers of the small intestine in rats. ( Haruma, K; Iida, M; Koga, H; Shimizu, K, 2007) |
| "To analyse the protective effect of a free radical scavenger, edaravone, on endolymphatic hydrops." | 3.74 | Protective effect of edaravone against endolymphatic hydrops. ( Anniko, M; Kakigi, A; Nakatani, H; Takeda, S; Takeda, T; Takumida, M, 2007) |
| " In the first, the dose-dependent effects of edaravone on ICH-induced brain injury were examined by measuring brain edema and neurologic deficits." | 3.74 | Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. ( Itano, T; Keep, RF; Kuroda, Y; Miyamoto, O; Nagao, S; Nakamura, T; Tamiya, T; Xi, G; Yamashita, S; Zhang, X, 2008) |
| "Intrathecally administered edaravone, a free radical scavenger, had analgesic effects on inflammatory-induced acute and facilitated pain but not on acute thermal pain, without any behavioural side-effects." | 3.73 | Intrathecal edaravone, a free radical scavenger, is effective on inflammatory-induced pain in rats. ( Nishiyama, T; Ogawa, M, 2005) |
| " The present study was undertaken to examine whether or not the free radical scavenger, edaravone, could prevent the extravasation of tPA administered for the purpose of fibrinolysis in a rat model of thromboembolic stroke." | 3.73 | Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. ( Harada, T; Kano, T; Katayama, Y, 2005) |
| "Compared to vehicle group, IR significantly decreased the PO(2) level and increased the wet-to-dry ratio, proteins in bronchoalveolar lavage (BAL), and myeloperoxidase (MPO) activity in the control group, while edaravone treatment maintained the PO(2) similar to the vehicle group and significantly reduced edema formation and neutrophil extravasation." | 3.73 | MCI-186 (edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A(2) in an isolated rat lung model after 18 h of cold preservation. ( Akamatsu, H; Reyes, YA; Shimoyama, T; Sunamori, M, 2006) |
| " In the present investigation, we examined the effects of the radical scavenger edaravone administered at various time points to rats with puromycin nephrosis." | 3.73 | Protective effect of radical scavenger edaravone against puromycin nephrosis. ( Ashida, A; Hirano, K; Matsumura, H; Nakakura, H; Tamai, H, 2006) |
| " This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures." | 2.61 | Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. ( Jaiswal, MK, 2019) |
| "Edaravone is a promising treatment for stroke." | 2.50 | Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review. ( Egan, K; Macleod, M; Mead, G; Sena, E; Wu, S, 2014) |
| "Edaravone is a mitochondrially targeted drug with a suggested capability to modify the course of diverse neurological diseases." | 1.91 | Experimental Treatment with Edaravone in a Mouse Model of Spinocerebellar Ataxia 1. ( Benediktova, S; Cendelin, J; Jedlicka, J; Jelinkova, D; Kapl, S; Kuncova, J; Purkartova, Z; Sucha, M; Tichanek, F; Tuma, J, 2023) |
| "The major hallmark of Parkinson's disease (PD) is the degeneration of dopaminergic neurons in the substantia nigra (SN), which is responsible for the core motor symptoms of PD." | 1.72 | The Effects of Novel Formulations of Edaravone and Curcumin in the Mouse Intrastriatal Lipopolysaccharide Model of Parkinson's Disease. ( Bobrovskaya, L; Deng, I; Garg, S; Zhou, XF, 2022) |
| "Depression is a very common mental disorder and mechanism that is associated with mitochondrial dysfunction." | 1.72 | Antidepressant-Like Effects of Edaravone and Minocycline: Investigation of Oxidative Stress, Neuroinflammation, Neurotrophic, and Apoptotic Pathways. ( Bagheri, A; Motafeghi, F; Seyedabadi, M; Shaki, F; Shokrzadeh, M, 2022) |
| " The present study demonstrates that the long-term administration of EDA may provide a promising therapeutic approach for WMLs in AD plus CCH disease with cognitive deficits." | 1.62 | Protective effects of edaravone on white matter pathology in a novel mouse model of Alzheimer's disease with chronic cerebral hypoperfusion. ( Abe, K; Feng, T; Hishikawa, N; Matsumoto, N; Sasaki, R; Tadokoro, K; Yamashita, T, 2021) |
| "Edaravone was administered intraperitoneally 30 min before radiotherapy (5 Gy)." | 1.62 | Protective effect of edaravone against radiation-induced ovarian injury: a histopathological and immunohistochemical evaluation in an experimental rat model. ( Alver, A; Gürlek, B; Mete Ural, Ü, 2021) |
| "Edaravone pretreatment suppressed epileptiform activity by reducing the mean spike frequency and the behavior scores in ECoG recording." | 1.62 | Anticonvulsive effects of edaravone on penicillin-induced focal onset seizure model in the conscious rats. ( Aygun, H; Kurt, S, 2021) |
| "Among all the treatments for Multiple Sclerosis, stem cell transplantation, such as ADSCs, has attracted a great deal of scientific attention." | 1.62 | Evaluation of Edaravone effects on the differentiation of human adipose derived stem cells into oligodendrocyte cells in multiple sclerosis disease in rats. ( Amirpour, N; Bakhtiari, M; Ghasemi, N; Kazemi, M; Mardani, M; Salehi, H, 2021) |
| "Edaravone is a potent free radical scavenger that has a promising role in combating many acute lung injuries." | 1.56 | Edaravone attenuates lung injury in a hind limb ischemia-reperfusion rat model: A histological, immunohistochemical and biochemical study. ( Aboregela, AM; Kassab, AA; Shalaby, AM, 2020) |
| "Edaravone has showed its neuroprotective effects after ischemia stroke, but its effects and possible mechanisms after ICH are poorly understood." | 1.56 | Edaravone Administration Confers Neuroprotection after Experimental Intracerebral Hemorrhage in Rats via NLRP3 Suppression. ( Geng, J; Jiang, Y; Miao, H; Tang, J; Zhang, B; Zhu, G, 2020) |
| "Edaravone (3 mg/kg) was administered intravenously to 14 C57BL/6 mice just before reperfusion." | 1.56 | Effects of Edaravone on Nitric Oxide, Hydroxyl Radicals and Neuronal Nitric Oxide Synthase During Cerebral Ischemia and Reperfusion in Mice. ( Araki, N; Hirayama, M; Ishizawa, K; Ito, Y; Kawasaki, H; Kitabayashi, C; Nagai, T; Nishioka, R; Takahashi, K; Tanaka, A; Yamamoto, T; Yamazato, M, 2020) |
| "Edaravone is a potent free radical scavenger that has a neuroprotective effect against memory impairment in several experimental models." | 1.56 | Edaravone protects from memory impairment induced by chronic L-methionine administration. ( Aburashed, ZO; Alzoubi, KH; Mayyas, F, 2020) |
| "Ischemia-reperfusion injury was induced through clamping the right femoral artery in rats, with a 4-h ischemia time in all experiments." | 1.56 | Oxidative stress evaluation of skeletal muscle in ischemia-reperfusion injury using enhanced magnetic resonance imaging. ( Haga, K; Kuroda, Y; Sadahiro, M; Togashi, H; Uchida, T; Yamashita, A, 2020) |
| "Edaravone (Edv) can inhibit tissue damage, cause cerebral edema, and delay neuronal death caused by acute cerebral infarction." | 1.56 | Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke. ( Li, F; Liang, J; Shi, Y; Zhao, L, 2020) |
| "Edaravone treatment significantly ameliorated neurological deficits, brain edema, and BBB disruption." | 1.51 | The Role of Oxidative Stress in Microvascular Disturbances after Experimental Subarachnoid Hemorrhage. ( Fumoto, T; Katagai, T; Li, Y; Naraoka, M; Ohkuma, H; Shimamura, N, 2019) |
| "Edaravone is a free radical scavenger, with a neuroprotective effect against cognitive impairment in several animal models." | 1.51 | Edaravone prevents memory impairment in an animal model of post-traumatic distress. ( Al-Qudah, MA; Alfaqih, MA; Alzoubi, KH; Shatnawi, A, 2019) |
| "Edaravone is a new type of oxygen free radical scavenger and able to attenuate various brain damage including hypoxic-ischemic brain damage (HIBD)." | 1.48 | Edaravone attenuates neuronal apoptosis in hypoxic-ischemic brain damage rat model via suppression of TRAIL signaling pathway. ( Fu, R; Huang, Y; Lei, J; Li, C; Li, H; Luo, S; Mo, Z; Zhang, L, 2018) |
| "Our results indicate that oral delivery of NEF holds a promise as a safe and effective therapeutic agent for AD." | 1.48 | Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model. ( Cao, X; Chen, C; Garg, S; Kathawala, K; Li, J; Parikh, A; Shan, Z; Wang, YJ; Zhou, XF, 2018) |
| "Edaravone is a novel free radical scavenger that exerts neuroprotective effects by inhibiting endothelial injury and by ameliorating neuronal damage in brain ischemia." | 1.46 | Edaravone injection reverses learning and memory deficits in a rat model of vascular dementia. ( Ge, X; Li, W; Li, X; Liang, X; Lu, F; Qin, L; Yao, Y; Yu, Q; Zhang, J; Zhao, D, 2017) |
| "The edaravone (20 mg/kg) was administered daily for 14 days from the induction of hydrocephalus." | 1.46 | Edaravone reduces astrogliosis and apoptosis in young rats with kaolin-induced hydrocephalus. ( Catalão, CHR; da Silva Lopes, L; Garcia, CAB; Júnior, IM; Machado, HR; Peixoto-Santos, JE; Romeiro, TH; Santos, MV, 2017) |
| "Edaravone was administered either intraperitoneally twice a day for 2 weeks or intravenously just once after laser photocoagulation." | 1.43 | Edaravone is a free radical scavenger that protects against laser-induced choroidal neovascularization in mice and common marmosets. ( Hara, H; Masuda, T; Nakamura, S; Shimazawa, M; Takata, S; Tsuruma, K, 2016) |
| "Rat transient middle cerebral artery occlusion (MCAO) model was established." | 1.43 | Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model. ( Chen, J; Ding, WS; Ding, XS; Liu, XF; Shen, HC; Shen, LH; Sheng, YF; Ye, M, 2016) |
| "Edaravone (18 mg/kg) treatment did not prevent hyperlocomotion in the mania model induced with ketamine in rats, but lithium chloride (47." | 1.43 | The effects of edaravone in ketamine-induced model of mania in rats. ( Altun, İK; Alver, A; Arslan, FC; Gedikli, Ö; İnce, İ; Özkorumak, E; Tiryaki, A; Yıldırım, M, 2016) |
| "Edaravone is a potent free radical scavenger that exerts antioxidant effects." | 1.42 | Edaravone injection ameliorates cognitive deficits in rat model of Alzheimer's disease. ( Li, F; Li, J; Liu, X; Wang, Q; Yang, R, 2015) |
| " Most importantly, 3d possessed a very high absolute bioavailability and was rapidly distributed in brain tissue to keep high plasma drug concentration for the treatment of ischemic strokes." | 1.42 | Discovery of 3-n-butyl-2,3-dihydro-1H-isoindol-1-one as a potential anti-ischemic stroke agent. ( Lan, Z; Lei, M; Li, J; Liang, Z; Xu, W; Xu, X; Zhang, X; Zhao, C, 2015) |
| "Edaravone is a free radical scavenger, and borneol has shown anti-inflammatory effect." | 1.40 | The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. ( Gao, LY; Hua, Y; Liao, GY; Luo, CX; Sun, WX; Tang, Y; Wu, HY; Yang, SB; Zhang, ZP; Zhou, QG; Zhu, DY, 2014) |
| "Treatment with edaravone significantly increased the number of NSPCs and newly generated neurons in the subgranular zone (p < ." | 1.40 | Pre- and posttreatment with edaravone protects CA1 hippocampus and enhances neurogenesis in the subgranular zone of dentate gyrus after transient global cerebral ischemia in rats. ( Chen, X; Gao, M; He, X; Lei, S; Li, W; Li, X; Liu, Y; Lu, H; Qi, C; Wang, N; Wang, X; Zhang, J; Zhang, P; Zheng, J, 2014) |
| "In vivo, both Edaravone and Scutellarin markedly reduced the infarct cerebral tissue area with the latter drug being more effective with the dosage used; furthermore, when used in combination the reduction was more substantial." | 1.40 | Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia. ( Ling, EA; Rangarajan, P; Wu, C; Yuan, Y; Zha, H, 2014) |
| "The edaravone-treated animals also exhibited higher rCBF in the contralateral hemisphere compared with that seen in -vehicle-treated animals." | 1.39 | Edaravone increases regional cerebral blood flow after traumatic brain injury in mice. ( Aruga, T; Dohi, K; Kiriyama, K; Miyamoto, K; Nakano, H; Ohtaki, H; Shioda, S; Song, D; Tsumuraya, T, 2013) |
| "These results support the critical role of NO in the microcirculation and suggest that free-radical scavenging increases the bioavailability of NO in the microcirculation via eNOS upregulation." | 1.39 | Effect of a free radical scavenger on nitric oxide release in microvessels. ( Sakamoto, K; Totani, N; Yamamoto, J; Yamanishi, H; Yamashita, T, 2013) |
| "Edaravone treatment significantly inhibited both lipid and DNA oxidative damage 72h after ischemia, and decreased neuronal damage." | 1.38 | Edaravone, a free radical scavenger, attenuates behavioral deficits following transient forebrain ischemia by inhibiting oxidative damage in gerbils. ( Hirooka, K; Itano, T; Kawai, N; Keep, RF; Liu, Y; Lu, F; Miyamoto, O; Nakamura, T; Okabe, N; Shiraga, F; Tamiya, T; Toyoshima, T, 2012) |
| "Edaravone treatment significantly reduced messenger RNA expressions of cytokines and matrix metalloproteinases (MMPs) in aneurysm walls (MMP-2: 1." | 1.38 | Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats. ( Hasegawa, T; Morimoto, K; Morimoto, N; Okada, K; Okita, Y; Tanaka, A; Wulan, B; Yu, J, 2012) |
| " Edaravone effectively protected against CNS-OT and the adverse effects of PFC." | 1.38 | Perfluorocarbon-facilitated CNS oxygen toxicity in rats: reversal by edaravone. ( Cai, Z; Li, R; Liu, S; Ni, X; Quock, RM; Sun, X; Xu, W; Zhang, R, 2012) |
| "In vivo, rat transient middle cerebral artery occlusion (MCAO) model was established." | 1.38 | Protective effects of MCI-186 on transplantation of bone marrow stromal cells in rat ischemic stroke model. ( Ding, XS; Gu, XS; Han, Q; Huang, H; Huang, HF; Liu, XF; Shen, LH; Wu, EB; Ye, M; Zhang, C, 2012) |
| "The degree of cerebral vasospasm was evaluated by measuring the diameter of each basilar artery, and the expression of Rho-kinase in the vascular wall was examined by western blotting." | 1.37 | Effect of a free radical scavenger, edaravone, on free radical reactions: related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model. ( Munakata, A; Ohkuma, H; Shimamura, N, 2011) |
| "Oral montelukast (0." | 1.37 | Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. ( Fang, SH; Shi, WZ; Wei, EQ; Zhang, YM; Zhao, R, 2011) |
| "Edaravone is a scavenger of hydroxyl radicals." | 1.37 | Protective effects of edaravone on experimental spinal cord injury in rats. ( Altaş, M; Aras, M; Oran, I; Ozgiray, E; Oztürk, OH; Serarslan, Y; Söğüt, S; Yurtseven, T; Zileli, M, 2011) |
| "Edaravone treatment significantly reduced the elevated malondialdehyde levels in rat lungs after acute pancreatitis, suggesting an important role for free radicals in acute pancreatitis-associated lung injury." | 1.36 | Protective effects of the free radical scavenger edaravone on acute pancreatitis-associated lung injury. ( Cai, ZY; Deng, XM; Hou, J; Hu, JY; Liu, SQ; Mao, YF; Ni, X; Yang, T; Zhu, XY, 2010) |
| "To validate this new model of reperfusion injury, we used two well characterized neuroprotectants, estrogen and edaravone." | 1.36 | A novel rodent model of reperfusion injury following occlusion of the middle cerebral artery. ( Connell, BJ; Saleh, TM, 2010) |
| "Mice subjected to 2-h filamental middle cerebral artery occlusion were treated with NBO (95% O2, during the ischemia) alone, with edaravone (1." | 1.35 | Combination effects of normobaric hyperoxia and edaravone on focal cerebral ischemia-induced neuronal damage in mice. ( Hara, H; Iwama, T; Nonaka, Y; Shimazawa, M; Yoshimura, S, 2008) |
| "Treatment with edaravone significantly ameliorated the clinical severity of EAE, and a reduced infiltration of lymphocytes was observed based on a histological analysis." | 1.35 | Edaravone, a free radical scavenger, ameliorates experimental autoimmune encephalomyelitis. ( Kinoshita, M; Kumanogoh, A; Kusunoki, S; Miyamoto, K; Moriya, M; Nakatsuji, Y; Okuno, T; Sakoda, S, 2008) |
| "Edaravone (MCI-186) is a newly developed antioxidative radical scavenger for the treatment of acute cerebral infarction, exerting neuroprotective effects against ischemic insult." | 1.35 | Neuroprotective effects of edaravone, a free radical scavenger, on the rat hippocampus after pilocarpine-induced status epilepticus. ( Abe, T; Anan, M; Fujiki, M; Kamida, T; Kobayashi, H; Ooba, H, 2009) |
| "Edaravone was given by intraperitoneal administration 1 h before the LPS challenge." | 1.35 | Preventive effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced lung injury in mice. ( Bando, M; Enomoto, M; Gejyo, F; Ohno, S; Soda, M; Sugiyama, Y; Suzuki, E; Tajima, S; Takada, T; Yamasawa, H, 2008) |
| "Edaravone is a lipophilic drug with multiple mechanisms of action." | 1.35 | The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. ( Lapchak, PA; Zivin, JA, 2009) |
| "Edaravone pretreatment reduced markedly the productions of ROS-HR and MDA and increased the activities of GSH-PX and SOD." | 1.35 | Pretreatment with edaravone reduces lung mitochondrial damage in an infant rabbit ischemia-reperfusion model. ( Chen, D; Chen, Y; Gu, H; Qiu, W; Zheng, L; Zhou, J, 2008) |
| "Edaravone may inhibit the number of apoptotic neuronal cells and 8-OHdG expression within 48 h after HI insult." | 1.35 | Edaravone inhibits DNA peroxidation and neuronal cell death in neonatal hypoxic-ischemic encephalopathy model rat. ( Goto, Y; Itoh, M; Miyazawa, T; Nonoyama, S; Takizawa, Y, 2009) |
| "Edaravone treatment shifted the %FAC(initial)–%FAC(final) relationship downward (P < 0." | 1.35 | Development of cardiac dysfunction induced by repetitive transient myocardial ischemia is inhibited by edaravone in conscious rats. ( Imai, K; Kawamoto, T; Miyamoto, Y; Neishi, Y; Okura, H; Toyota, E; Yoshida, K, 2009) |
| "The edaravone-treated SC group demonstrated less severe apoptosis than the untreated SC group." | 1.35 | [Effects of edaravone on IRE1 mRNA expression and neuronal apoptosis in the hippocampus of rats with status convulsivus]. ( Deng, XL; Jiao, Y; Li, GQ, 2009) |
| "Edaravone is a novel free radical scavenger that is clinically employed in patients with acute cerebral infarction, but has not previously been used to treat traumatic brain injury (TBI)." | 1.35 | The novel free radical scavenger, edaravone, increases neural stem cell number around the area of damage following rat traumatic brain injury. ( Hashimoto, S; Ito, H; Itoh, T; Nishida, S; Satou, T; Tsubaki, M, 2009) |
| "Pretreatment with edaravone scavenged the SN38-produced reactive oxygen species, and inhibited the SN38-induced activation of NF-kB." | 1.33 | The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB. ( Handa, O; Higashihara, H; Ishikawa, T; Kokura, S; Naito, Y; Nakabe, N; Sakamoto, N; Takagi, T; Yoshida, N; Yoshikawa, T, 2005) |
| "Edaravone (10 mg/kg) was delivered intravenously before ischemia and after reperfusion to prevent the neutrophil activation." | 1.33 | Treatment with edaravone improves the survival rate in renal warm ischemia-reperfusion injury using rat model. ( Funao, K; Hayama, T; Kawahito, Y; Matsuyama, M; Nakatani, T; Sano, H; Sugimura, K; Takemoto, Y; Tsuchida, K; Yoshimura, R, 2006) |
| "Edaravone treatment induces significant reduction of free radical precursors and their metabolites compared with controls in burn rats." | 1.33 | The therapeutic efficacy of edaravone in extensively burned rats. ( Koizumi, T; Sakaki, S; Shimazaki, S; Tanaka, H, 2006) |
| "Edaravone+tPA-treated group: Edaravone (3 mg/kg, i." | 1.32 | Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. ( Abe, K; Hayashi, T; Horiuchi, S; Kato, S; Nagano, I; Omori, N; Sato, K; Zhang, W, 2004) |
| "Cerebral vasospasm is one of the important pathological phenomena which influence morbidity and mortality following subarachnoid haemorrhage." | 1.31 | Contractile responses to reactive oxygen species in the canine basilar artery in vitro: selective inhibitory effect of MCI-186, a new hydroxyl radical scavenger. ( Hashiba, Y; Imai, H; Saito, N; Sasaki, T; Shimizu, T; Tosaka, M, 2002) |
| "The volume of cerebral infarction, induced by 2-h occlusion and subsequent 2-h reperfusion of MCA in Fisher-344 rats, was evaluated." | 1.30 | Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. ( Iwai, T; Nakashima, M; Niwa, M; Uematsu, T, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.23) | 18.2507 |
| 2000's | 45 (27.61) | 29.6817 |
| 2010's | 86 (52.76) | 24.3611 |
| 2020's | 30 (18.40) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 4 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Wang, H | 2 |
| Cui, E | 1 |
| Li, J | 5 |
| Ma, X | 1 |
| Jiang, X | 1 |
| Du, S | 1 |
| Qian, S | 1 |
| Du, L | 1 |
| Hua, Y | 2 |
| Zhou, L | 1 |
| Yang, W | 1 |
| An, W | 1 |
| Kou, X | 1 |
| Ren, J | 1 |
| Su, H | 1 |
| Chen, R | 1 |
| Zhang, Z | 1 |
| Zou, J | 1 |
| Zhao, Z | 1 |
| Guan, Y | 1 |
| Li, P | 1 |
| Liu, Y | 5 |
| Guo, L | 1 |
| Wu, Q | 1 |
| Cheng, Y | 1 |
| Deng, I | 1 |
| Garg, S | 2 |
| Zhou, XF | 3 |
| Bobrovskaya, L | 1 |
| Zhao, G | 2 |
| Zhao, L | 4 |
| Li, Y | 5 |
| Wang, L | 2 |
| Hu, Z | 2 |
| Motafeghi, F | 2 |
| Bagheri, A | 2 |
| Seyedabadi, M | 2 |
| Shaki, F | 2 |
| Shokrzadeh, M | 2 |
| Sucha, M | 1 |
| Benediktova, S | 1 |
| Tichanek, F | 1 |
| Jedlicka, J | 1 |
| Kapl, S | 1 |
| Jelinkova, D | 1 |
| Purkartova, Z | 1 |
| Tuma, J | 1 |
| Kuncova, J | 1 |
| Cendelin, J | 1 |
| Anoush, M | 1 |
| Bijani, S | 1 |
| Moslemifar, F | 1 |
| Jahanpour, F | 1 |
| Kalantari-Hesari, A | 1 |
| Hosseini, MJ | 1 |
| Wang, XB | 2 |
| Zhou, LY | 1 |
| Chen, XQ | 1 |
| Li, R | 3 |
| Yu, BB | 1 |
| Pan, MX | 1 |
| Fang, L | 1 |
| Cui, XJ | 1 |
| Yao, M | 1 |
| Lu, X | 1 |
| Feng, T | 2 |
| Yamashita, T | 9 |
| Shang, J | 3 |
| Shi, X | 2 |
| Nakano, Y | 2 |
| Morihara, R | 1 |
| Tsunoda, K | 2 |
| Nomura, E | 2 |
| Sasaki, R | 3 |
| Tadokoro, K | 3 |
| Matsumoto, N | 2 |
| Hishikawa, N | 3 |
| Ohta, Y | 3 |
| Abe, K | 10 |
| Tian, F | 3 |
| Li, X | 5 |
| Liu, X | 3 |
| Sato, K | 2 |
| Takemoto, M | 1 |
| Kassab, AA | 1 |
| Aboregela, AM | 1 |
| Shalaby, AM | 1 |
| Miao, H | 1 |
| Jiang, Y | 1 |
| Geng, J | 1 |
| Zhang, B | 1 |
| Zhu, G | 1 |
| Tang, J | 1 |
| Kawasaki, H | 1 |
| Ito, Y | 1 |
| Kitabayashi, C | 1 |
| Tanaka, A | 2 |
| Nishioka, R | 1 |
| Yamazato, M | 1 |
| Ishizawa, K | 1 |
| Nagai, T | 1 |
| Hirayama, M | 1 |
| Takahashi, K | 1 |
| Yamamoto, T | 1 |
| Araki, N | 1 |
| Alzoubi, KH | 2 |
| Aburashed, ZO | 1 |
| Mayyas, F | 1 |
| Fu, ZY | 1 |
| Wu, ZJ | 1 |
| Zheng, JH | 1 |
| Li, N | 2 |
| Lu, JY | 1 |
| Chen, MH | 2 |
| Demir, F | 1 |
| Demir, M | 1 |
| Aygun, H | 3 |
| Hao, L | 1 |
| Dong, L | 1 |
| Yu, Q | 2 |
| Shen, W | 1 |
| Wei, X | 1 |
| Kuroda, Y | 2 |
| Togashi, H | 1 |
| Uchida, T | 1 |
| Haga, K | 1 |
| Yamashita, A | 1 |
| Sadahiro, M | 1 |
| Yu, H | 1 |
| Wu, Z | 1 |
| Wang, X | 2 |
| Gao, C | 1 |
| Liu, R | 1 |
| Kang, F | 1 |
| Dai, M | 1 |
| Li, F | 2 |
| Shi, Y | 1 |
| Liang, J | 1 |
| Yamato, SH | 1 |
| Nakamura, S | 3 |
| Htun, Y | 1 |
| Nakamura, M | 1 |
| Jinnai, W | 1 |
| Nakao, Y | 1 |
| Mitsuie, T | 1 |
| Koyano, K | 1 |
| Wakabayashi, T | 1 |
| Morimoto, AH | 1 |
| Sugino, M | 1 |
| Iwase, T | 1 |
| Kondo, SI | 1 |
| Yasuda, S | 1 |
| Ueno, M | 1 |
| Miki, T | 1 |
| Kusaka, T | 1 |
| Mete Ural, Ü | 1 |
| Gürlek, B | 1 |
| Alver, A | 2 |
| Kurt, S | 1 |
| Atallah, M | 1 |
| Wang, XX | 1 |
| Wang, F | 1 |
| Mao, GH | 1 |
| Wu, JC | 1 |
| Li, M | 1 |
| Han, R | 1 |
| She, J | 1 |
| Zhang, R | 2 |
| Sheng, R | 1 |
| Chen, Z | 2 |
| Qin, ZH | 1 |
| Youssef, MI | 1 |
| Ma, J | 1 |
| Hu, WW | 1 |
| Bakhtiari, M | 1 |
| Ghasemi, N | 1 |
| Salehi, H | 1 |
| Amirpour, N | 1 |
| Kazemi, M | 1 |
| Mardani, M | 1 |
| Matsumoto, M | 1 |
| Miyamoto, M | 1 |
| Sawahata, M | 1 |
| Izumi, Y | 1 |
| Takada-Takatori, Y | 1 |
| Kume, T | 1 |
| Sawada, H | 1 |
| Akaiwa, K | 1 |
| Namekata, K | 2 |
| Azuchi, Y | 2 |
| Guo, X | 3 |
| Kimura, A | 2 |
| Harada, C | 2 |
| Mitamura, Y | 1 |
| Harada, T | 3 |
| Ando, S | 1 |
| Funato, M | 1 |
| Ohuchi, K | 1 |
| Kameyama, T | 1 |
| Inagaki, S | 1 |
| Seki, J | 1 |
| Kawase, C | 1 |
| Tsuruma, K | 3 |
| Shimazawa, M | 5 |
| Kaneko, H | 1 |
| Hara, H | 5 |
| Kapoor, S | 1 |
| Akiyama, G | 1 |
| Noro, T | 1 |
| Zhang, D | 1 |
| Xiao, Y | 1 |
| Lv, P | 1 |
| Teng, Z | 1 |
| Dong, Y | 1 |
| Qi, Q | 1 |
| Liu, Z | 1 |
| Ishii, H | 2 |
| Petrenko, AB | 1 |
| Sasaki, M | 1 |
| Satoh, Y | 1 |
| Kamiya, Y | 1 |
| Tobita, T | 1 |
| Furutani, K | 1 |
| Matsuhashi, M | 1 |
| Kohno, T | 1 |
| Baba, H | 1 |
| Li, C | 1 |
| Mo, Z | 1 |
| Lei, J | 1 |
| Li, H | 1 |
| Fu, R | 1 |
| Huang, Y | 1 |
| Luo, S | 1 |
| Zhang, L | 2 |
| Parikh, A | 1 |
| Kathawala, K | 1 |
| Chen, C | 1 |
| Shan, Z | 1 |
| Cao, X | 1 |
| Wang, YJ | 1 |
| Jaiswal, MK | 1 |
| Liu, LM | 1 |
| Wang, N | 3 |
| Lu, Y | 1 |
| Wang, WP | 1 |
| Fumoto, T | 1 |
| Naraoka, M | 1 |
| Katagai, T | 1 |
| Shimamura, N | 2 |
| Ohkuma, H | 2 |
| Guo, Y | 2 |
| Ma, Z | 1 |
| Li, T | 1 |
| Liu, J | 2 |
| Sun, M | 1 |
| Jian, Y | 1 |
| Yao, L | 1 |
| Du, Y | 1 |
| Zhang, G | 1 |
| Shatnawi, A | 1 |
| Al-Qudah, MA | 1 |
| Alfaqih, MA | 1 |
| Liang, C | 1 |
| He, Q | 1 |
| Ge, F | 1 |
| Yin, X | 1 |
| Basol, N | 1 |
| Gul, SS | 1 |
| Herbet, M | 1 |
| Natorska-Chomicka, D | 1 |
| Ostrowska, M | 1 |
| Gawrońska-Grzywacz, M | 1 |
| Izdebska, M | 1 |
| Piątkowska-Chmiel, I | 1 |
| Korga, A | 1 |
| Wróbel, A | 1 |
| Dudka, J | 1 |
| Miyamoto, K | 3 |
| Ohtaki, H | 2 |
| Dohi, K | 2 |
| Tsumuraya, T | 2 |
| Nakano, H | 1 |
| Kiriyama, K | 2 |
| Song, D | 2 |
| Aruga, T | 2 |
| Shioda, S | 2 |
| Satoh, K | 1 |
| Shimizu, A | 1 |
| Deguchi, K | 3 |
| Omote, Y | 2 |
| Kawai, H | 3 |
| Miyamoto, N | 1 |
| Maki, T | 1 |
| Pham, LD | 1 |
| Hayakawa, K | 1 |
| Seo, JH | 1 |
| Mandeville, ET | 1 |
| Mandeville, JB | 1 |
| Kim, KW | 1 |
| Lo, EH | 1 |
| Arai, K | 1 |
| Wu, S | 1 |
| Sena, E | 1 |
| Egan, K | 1 |
| Macleod, M | 1 |
| Mead, G | 1 |
| Hato, N | 1 |
| Kohno, H | 1 |
| Yamada, H | 1 |
| Takahashi, H | 1 |
| Gyo, K | 1 |
| Zhang, GM | 1 |
| Wang, Y | 3 |
| Li, XY | 1 |
| Xu, L | 1 |
| Sun, YY | 2 |
| Li, YZ | 1 |
| Liu, LF | 1 |
| Hashimoto, T | 2 |
| Shibata, K | 2 |
| Ohata, H | 1 |
| Hasumi, K | 2 |
| Honda, K | 2 |
| He, F | 1 |
| Cao, YP | 1 |
| Che, FY | 1 |
| Yang, LH | 1 |
| Xiao, SH | 1 |
| Morozov, YM | 1 |
| Yang, D | 1 |
| Dunn, RS | 1 |
| Rakic, P | 1 |
| Chan, PH | 1 |
| Lindquist, DM | 1 |
| Kuan, CY | 1 |
| Liu, N | 3 |
| Liu, W | 1 |
| Kono, S | 1 |
| Yunoki, T | 1 |
| Deguchi, S | 1 |
| Ikeda, Y | 1 |
| Wang, J | 1 |
| Ma, XJ | 1 |
| Zong, Y | 1 |
| Yuan, BJ | 1 |
| Zhao, LJ | 1 |
| Lu, GC | 1 |
| Wu, HY | 1 |
| Tang, Y | 1 |
| Gao, LY | 1 |
| Sun, WX | 1 |
| Yang, SB | 1 |
| Zhang, ZP | 1 |
| Liao, GY | 1 |
| Zhou, QG | 1 |
| Luo, CX | 1 |
| Zhu, DY | 1 |
| Lei, S | 2 |
| Zhang, P | 2 |
| Gao, M | 3 |
| He, X | 1 |
| Zheng, J | 2 |
| Zhang, J | 4 |
| Qi, C | 1 |
| Lu, H | 2 |
| Chen, X | 3 |
| Yuan, Y | 1 |
| Zha, H | 1 |
| Rangarajan, P | 1 |
| Ling, EA | 1 |
| Wu, C | 1 |
| Zuo, W | 1 |
| Zhang, W | 2 |
| Han, N | 2 |
| Chen, NH | 1 |
| Wang, Z | 1 |
| Chen, W | 1 |
| Xu, S | 2 |
| Duan, J | 1 |
| Chen, Y | 4 |
| Wang, C | 2 |
| Chiazza, F | 1 |
| Chegaev, K | 1 |
| Rogazzo, M | 1 |
| Cutrin, JC | 1 |
| Benetti, E | 1 |
| Lazzarato, L | 1 |
| Fruttero, R | 1 |
| Collino, M | 1 |
| Hassan, MQ | 1 |
| Akhtar, MS | 1 |
| Akhtar, M | 1 |
| Ali, J | 1 |
| Haque, SE | 1 |
| Najmi, AK | 1 |
| Sato, T | 1 |
| Sakamoto, K | 2 |
| Yamamoto, J | 2 |
| Yang, R | 1 |
| Wang, Q | 1 |
| Lan, Z | 1 |
| Xu, X | 1 |
| Xu, W | 3 |
| Liang, Z | 1 |
| Zhang, X | 3 |
| Lei, M | 1 |
| Zhao, C | 1 |
| Liu, L | 1 |
| Song, Y | 1 |
| Zhao, M | 1 |
| Yi, Z | 1 |
| Zeng, Q | 1 |
| Ikeda, K | 1 |
| Iwasaki, Y | 2 |
| Sriram, CS | 1 |
| Jangra, A | 1 |
| Gurjar, SS | 1 |
| Mohan, P | 1 |
| Bezbaruah, BK | 1 |
| Wang, S | 1 |
| Lu, Z | 1 |
| Masuda, T | 1 |
| Takata, S | 1 |
| Zhang, GW | 1 |
| Gu, TX | 1 |
| Sun, XJ | 1 |
| Qi, X | 1 |
| Li-Ling, J | 1 |
| Wang, P | 1 |
| Cao, J | 1 |
| Ma, L | 1 |
| Zhou, X | 1 |
| Zhang, H | 1 |
| Shen, LH | 2 |
| Chen, J | 1 |
| Shen, HC | 1 |
| Ye, M | 2 |
| Liu, XF | 2 |
| Ding, WS | 1 |
| Sheng, YF | 1 |
| Ding, XS | 2 |
| Zhu, Y | 1 |
| Liu, C | 1 |
| Sun, Z | 1 |
| Zhang, Y | 1 |
| Yang, Y | 1 |
| Zhang, GZ | 1 |
| Ge, GZ | 1 |
| Wang, QQ | 1 |
| Ji, XC | 1 |
| Sun, YL | 1 |
| Zhang, HT | 1 |
| Xu, RX | 1 |
| Qin, T | 1 |
| Lei, LY | 1 |
| Shi, FR | 1 |
| Xie, L | 1 |
| Arslan, FC | 1 |
| Tiryaki, A | 1 |
| Yıldırım, M | 1 |
| Özkorumak, E | 1 |
| Altun, İK | 1 |
| İnce, İ | 1 |
| Gedikli, Ö | 1 |
| Lu, F | 2 |
| Qin, L | 1 |
| Yao, Y | 1 |
| Ge, X | 1 |
| Liang, X | 1 |
| Zhao, D | 1 |
| Garcia, CAB | 1 |
| Catalão, CHR | 1 |
| Machado, HR | 1 |
| Júnior, IM | 1 |
| Romeiro, TH | 1 |
| Peixoto-Santos, JE | 1 |
| Santos, MV | 1 |
| da Silva Lopes, L | 1 |
| Zhang, DY | 1 |
| Kang, SS | 1 |
| Zhang, ZW | 1 |
| Wu, R | 1 |
| Uji, Y | 1 |
| Yamamoto, H | 1 |
| Mori, T | 1 |
| Akabori, H | 1 |
| Tsuchihashi, H | 1 |
| Shimizu, T | 2 |
| Endo, Y | 1 |
| Tani, T | 1 |
| Nonaka, Y | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Moriya, M | 1 |
| Nakatsuji, Y | 1 |
| Okuno, T | 1 |
| Kinoshita, M | 1 |
| Kumanogoh, A | 1 |
| Kusunoki, S | 1 |
| Sakoda, S | 1 |
| Kamida, T | 1 |
| Fujiki, M | 1 |
| Ooba, H | 1 |
| Anan, M | 1 |
| Abe, T | 1 |
| Kobayashi, H | 1 |
| Tajima, S | 1 |
| Soda, M | 1 |
| Bando, M | 1 |
| Enomoto, M | 1 |
| Yamasawa, H | 1 |
| Ohno, S | 1 |
| Takada, T | 1 |
| Suzuki, E | 1 |
| Gejyo, F | 1 |
| Sugiyama, Y | 1 |
| Lapchak, PA | 1 |
| Zivin, JA | 1 |
| Qiu, W | 1 |
| Gu, H | 1 |
| Zheng, L | 1 |
| Zhou, J | 1 |
| Chen, D | 1 |
| Xu, JZ | 1 |
| Shen, BZ | 1 |
| Zhang, T | 1 |
| Xu, WH | 1 |
| Liu, XW | 1 |
| Lu, HG | 1 |
| Ding, SJ | 1 |
| Wu, T | 1 |
| Zhu, YL | 1 |
| Zhang, YM | 2 |
| Liu, XH | 1 |
| Zhang, DW | 1 |
| Inokuchi, Y | 1 |
| Imai, S | 2 |
| Nakajima, Y | 1 |
| Aihara, M | 1 |
| Araie, M | 1 |
| Sonoda, A | 2 |
| Nitta, N | 2 |
| Seko, A | 2 |
| Ohta, S | 3 |
| Takemura, S | 2 |
| Miyagawa, Y | 1 |
| Takahashi, M | 2 |
| Murata, K | 2 |
| Takizawa, Y | 1 |
| Miyazawa, T | 1 |
| Nonoyama, S | 1 |
| Goto, Y | 1 |
| Itoh, M | 1 |
| Takahashi, R | 1 |
| Zhou, F | 1 |
| Chen, G | 1 |
| Toyota, E | 1 |
| Miyamoto, Y | 1 |
| Imai, K | 1 |
| Neishi, Y | 1 |
| Kawamoto, T | 1 |
| Okura, H | 1 |
| Yoshida, K | 1 |
| Sugimoto, T | 1 |
| Uzu, T | 1 |
| Yokomaku, Y | 1 |
| Kashiwagi, A | 1 |
| Jiao, Y | 1 |
| Deng, XL | 1 |
| Li, GQ | 1 |
| Itoh, T | 1 |
| Satou, T | 1 |
| Nishida, S | 1 |
| Tsubaki, M | 1 |
| Hashimoto, S | 1 |
| Ito, H | 1 |
| Martínez-Romero, R | 1 |
| Cañuelo, A | 1 |
| Martínez-Lara, E | 1 |
| Javier Oliver, F | 1 |
| Cárdenas, S | 1 |
| Siles, E | 1 |
| Kikuchi, K | 1 |
| Tancharoen, S | 1 |
| Matsuda, F | 1 |
| Biswas, KK | 1 |
| Ito, T | 1 |
| Morimoto, Y | 1 |
| Oyama, Y | 1 |
| Takenouchi, K | 1 |
| Miura, N | 1 |
| Arimura, N | 1 |
| Nawa, Y | 1 |
| Meng, X | 1 |
| Shrestha, B | 1 |
| Arimura, S | 1 |
| Iwata, M | 1 |
| Mera, K | 1 |
| Sameshima, H | 2 |
| Ohno, Y | 1 |
| Maenosono, R | 1 |
| Tajima, Y | 1 |
| Uchikado, H | 1 |
| Kuramoto, T | 1 |
| Nakayama, K | 1 |
| Shigemori, M | 1 |
| Yoshida, Y | 1 |
| Hashiguchi, T | 1 |
| Maruyama, I | 1 |
| Kawahara, K | 1 |
| Yang, T | 1 |
| Mao, YF | 1 |
| Liu, SQ | 1 |
| Hou, J | 1 |
| Cai, ZY | 1 |
| Hu, JY | 1 |
| Ni, X | 2 |
| Deng, XM | 1 |
| Zhu, XY | 1 |
| Shi, M | 1 |
| Cao, TW | 1 |
| Shen, L | 1 |
| Sun, ZD | 1 |
| Zhu, HC | 1 |
| Kojima, T | 1 |
| Ueda, Y | 2 |
| Adati, N | 1 |
| Kitamoto, A | 1 |
| Sato, A | 1 |
| Huang, MC | 1 |
| Noor, J | 1 |
| Ikenoue, T | 2 |
| Fu, JQ | 1 |
| Wang, DF | 1 |
| Liu, H | 2 |
| Zhao, YN | 1 |
| Gao, JL | 1 |
| Chen, HH | 1 |
| Tian, YX | 1 |
| Cui, JZ | 1 |
| Connell, BJ | 1 |
| Saleh, TM | 1 |
| Shimazaki, H | 1 |
| Watanabe, K | 3 |
| Veeraveedu, PT | 2 |
| Harima, M | 2 |
| Thandavarayan, RA | 2 |
| Arozal, W | 1 |
| Tachikawa, H | 1 |
| Kodama, M | 3 |
| Aizawa, Y | 2 |
| Lukic-Panin, V | 1 |
| Matsuura, T | 1 |
| Munakata, A | 1 |
| Iwashita, Y | 1 |
| Kakinoki, R | 1 |
| Noguchi, T | 1 |
| Nakamura, T | 3 |
| Jiao, L | 1 |
| Li, Z | 1 |
| Nomoto, J | 1 |
| Kuroki, T | 1 |
| Nemoto, M | 1 |
| Kondo, K | 1 |
| Harada, N | 1 |
| Nagao, T | 1 |
| Aoki, M | 1 |
| Warita, H | 1 |
| Mizuno, H | 1 |
| Suzuki, N | 1 |
| Yuki, S | 2 |
| Itoyama, Y | 2 |
| Roh, MI | 1 |
| Murakami, Y | 1 |
| Thanos, A | 1 |
| Vavvas, DG | 1 |
| Miller, JW | 1 |
| Miyazaki, Y | 1 |
| Kaikita, K | 1 |
| Endo, M | 1 |
| Horio, E | 1 |
| Miura, M | 1 |
| Tsujita, K | 1 |
| Hokimoto, S | 1 |
| Yamamuro, M | 1 |
| Iwawaki, T | 1 |
| Gotoh, T | 1 |
| Ogawa, H | 1 |
| Oike, Y | 1 |
| Zhao, R | 1 |
| Shi, WZ | 1 |
| Fang, SH | 1 |
| Wei, EQ | 1 |
| Nobe, K | 1 |
| Yoshizaki, A | 1 |
| Yanaba, K | 1 |
| Ogawa, A | 1 |
| Iwata, Y | 1 |
| Ogawa, F | 1 |
| Takenaka, M | 1 |
| Shimizu, K | 2 |
| Asano, Y | 1 |
| Kadono, T | 1 |
| Sato, S | 1 |
| Herlambang, B | 1 |
| Orihashi, K | 1 |
| Mizukami, T | 1 |
| Takahashi, S | 1 |
| Uchida, N | 1 |
| Hiyama, E | 1 |
| Sueda, T | 1 |
| Toyoshima, T | 1 |
| Hirooka, K | 1 |
| Kawai, N | 1 |
| Okabe, N | 1 |
| Shiraga, F | 1 |
| Tamiya, T | 2 |
| Miyamoto, O | 2 |
| Keep, RF | 2 |
| Itano, T | 2 |
| Ogishima, H | 1 |
| Nakanishi, T | 1 |
| Kakino, M | 1 |
| Ishizuka, F | 1 |
| Li, L | 1 |
| Ozgiray, E | 1 |
| Serarslan, Y | 1 |
| Oztürk, OH | 1 |
| Altaş, M | 1 |
| Aras, M | 1 |
| Söğüt, S | 1 |
| Yurtseven, T | 1 |
| Oran, I | 1 |
| Zileli, M | 1 |
| Morimoto, K | 1 |
| Hasegawa, T | 1 |
| Wulan, B | 1 |
| Yu, J | 1 |
| Morimoto, N | 1 |
| Okita, Y | 1 |
| Okada, K | 1 |
| Arumugam, S | 1 |
| Giridharan, VV | 1 |
| Soetikno, V | 1 |
| Suzuki, K | 2 |
| Nagata, M | 1 |
| Tagaki, R | 1 |
| Liu, S | 1 |
| Cai, Z | 1 |
| Sun, X | 1 |
| Quock, RM | 1 |
| Shimoda, M | 1 |
| Okada, T | 1 |
| Kubota, K | 1 |
| Han, Q | 1 |
| Zhang, C | 1 |
| Huang, H | 1 |
| Wu, EB | 1 |
| Huang, HF | 1 |
| Gu, XS | 1 |
| Monturiol-Gross, L | 1 |
| Flores-Díaz, M | 1 |
| Araya-Castillo, C | 1 |
| Pineda-Padilla, MJ | 1 |
| Clark, GC | 1 |
| Titball, RW | 1 |
| Alape-Girón, A | 1 |
| Yamanishi, H | 1 |
| Totani, N | 1 |
| Somekawa-Kondo, T | 1 |
| Yamaguchi, K | 1 |
| Ishitsuka, Y | 1 |
| Ito, S | 1 |
| Tanaka, K | 1 |
| Irikura, M | 1 |
| Moriuchi, H | 1 |
| Takahama, K | 1 |
| Ando, Y | 1 |
| Yamazaki, T | 1 |
| Irie, T | 1 |
| Wu, TW | 1 |
| Zeng, LH | 1 |
| Wu, J | 1 |
| Fung, KP | 1 |
| Tosaka, M | 1 |
| Hashiba, Y | 1 |
| Saito, N | 1 |
| Imai, H | 1 |
| Sasaki, T | 1 |
| Kono, H | 1 |
| Asakawa, M | 1 |
| Fujii, H | 1 |
| Maki, A | 1 |
| Amemiya, H | 1 |
| Yamamoto, M | 2 |
| Matsuda, M | 1 |
| Matsumoto, Y | 1 |
| Takahashi, G | 1 |
| Sakurai, M | 1 |
| Tabayashi, K | 1 |
| Hayashi, T | 1 |
| Omori, N | 1 |
| Nagano, I | 1 |
| Kato, S | 1 |
| Horiuchi, S | 1 |
| Yokoyama, H | 1 |
| Itoh, O | 1 |
| Ikeda, T | 1 |
| Noor, JI | 1 |
| Nishiyama, T | 1 |
| Ogawa, M | 1 |
| Kano, T | 1 |
| Katayama, Y | 1 |
| Kokura, S | 1 |
| Yoshida, N | 1 |
| Sakamoto, N | 1 |
| Ishikawa, T | 1 |
| Takagi, T | 1 |
| Higashihara, H | 1 |
| Nakabe, N | 1 |
| Handa, O | 1 |
| Naito, Y | 1 |
| Yoshikawa, T | 1 |
| Araki, Y | 1 |
| Sugihara, H | 1 |
| Hattori, T | 1 |
| Reyes, YA | 1 |
| Shimoyama, T | 1 |
| Akamatsu, H | 1 |
| Sunamori, M | 1 |
| Koray, AK | 1 |
| Tekeli, A | 1 |
| Isbir, S | 1 |
| Xi, H | 1 |
| Akishita, M | 1 |
| Nagai, K | 1 |
| Yu, W | 1 |
| Hasegawa, H | 1 |
| Eto, M | 1 |
| Kozaki, K | 1 |
| Toba, K | 1 |
| Matsuyama, M | 1 |
| Hayama, T | 1 |
| Funao, K | 1 |
| Tsuchida, K | 1 |
| Takemoto, Y | 1 |
| Sugimura, K | 1 |
| Kawahito, Y | 1 |
| Sano, H | 1 |
| Nakatani, T | 1 |
| Yoshimura, R | 1 |
| Koizumi, T | 1 |
| Tanaka, H | 1 |
| Sakaki, S | 1 |
| Shimazaki, S | 1 |
| Matsumura, H | 1 |
| Ashida, A | 1 |
| Hirano, K | 1 |
| Nakakura, H | 1 |
| Tamai, H | 2 |
| Suzuki, T | 1 |
| Kazui, T | 1 |
| Yamamoto, S | 1 |
| Washiyama, N | 1 |
| Ohkura, K | 1 |
| Ohishi, K | 1 |
| Bashar, AH | 1 |
| Yamashita, K | 1 |
| Terada, H | 1 |
| Akuzawa, S | 1 |
| Fujie, M | 1 |
| Ma, M | 1 |
| Wen, J | 1 |
| Koga, H | 1 |
| Iida, M | 1 |
| Haruma, K | 1 |
| Takumida, M | 1 |
| Takeda, T | 1 |
| Takeda, S | 1 |
| Kakigi, A | 1 |
| Nakatani, H | 1 |
| Anniko, M | 1 |
| Xiao, B | 1 |
| Bi, FF | 1 |
| Hu, YQ | 1 |
| Tian, FF | 1 |
| Wu, ZG | 1 |
| Mujlli, HM | 1 |
| Ding, L | 1 |
| Yamashita, S | 1 |
| Nagao, S | 1 |
| Xi, G | 1 |
| Miyamoto, R | 1 |
| Shimakawa, S | 1 |
| Suzuki, S | 1 |
| Ogihara, T | 1 |
| Radhakrishnan, G | 1 |
| Suzuki, R | 1 |
| Maeda, H | 1 |
| Hirose, N | 1 |
| Gopalrao, RK | 1 |
| Lee, GH | 1 |
| Hayashi, Y | 1 |
| Rao, P | 1 |
| Sasaguri, S | 1 |
| Nakai, H | 1 |
| Suga, M | 1 |
| Watanabe, T | 1 |
| Saito, KI | 1 |
| Nakashima, M | 1 |
| Niwa, M | 1 |
| Iwai, T | 1 |
| Uematsu, T | 1 |
4 reviews available for edaravone and Disease Models, Animal
| Article | Year |
|---|---|
Potential therapeutic agents for ischemic white matter damage.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Disease Models, Animal; Edaravone; H | 2021 |
Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Disease Models, Animal; Edaravone; Free Radical | 2017 |
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Clinical Trials as Topic; Disease Models, Anim | 2019 |
Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review.
Topics: Animals; Antipyrine; Brain; Brain Ischemia; Disease Models, Animal; Edaravone; Free Radical Scavenge | 2014 |
159 other studies available for edaravone and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cyclooxygenase 2; Disease Models, Animal; Indazol | 2022 |
Y-2 reduces oxidative stress and inflammation and improves neurological function of collagenase-induced intracerebral hemorrhage rats.
Topics: Animals; Brain Edema; Camphanes; Cerebral Hemorrhage; Collagenases; Disease Models, Animal; Drug Com | 2021 |
Protective multi‑target effects of DL‑3‑n‑butylphthalide combined with 3‑methyl‑1‑phenyl‑2‑pyrazolin‑5‑one in mice with ischemic stroke.
Topics: Animals; Apoptosis Regulatory Proteins; Benzofurans; Brain Ischemia; Disease Models, Animal; Drug Th | 2021 |
The Effects of Novel Formulations of Edaravone and Curcumin in the Mouse Intrastriatal Lipopolysaccharide Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Anti-Inflammatory Agents; Curcumin; Disease Models, Animal; Edaravone; Lip | 2022 |
Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury.
Topics: Animals; Apoptosis; Disease Models, Animal; Edaravone; Interleukin-6; Ischemia; Oxidative Stress; Ra | 2022 |
Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury.
Topics: Animals; Apoptosis; Disease Models, Animal; Edaravone; Interleukin-6; Ischemia; Oxidative Stress; Ra | 2022 |
Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury.
Topics: Animals; Apoptosis; Disease Models, Animal; Edaravone; Interleukin-6; Ischemia; Oxidative Stress; Ra | 2022 |
Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury.
Topics: Animals; Apoptosis; Disease Models, Animal; Edaravone; Interleukin-6; Ischemia; Oxidative Stress; Ra | 2022 |
Antidepressant-Like Effects of Edaravone and Minocycline: Investigation of Oxidative Stress, Neuroinflammation, Neurotrophic, and Apoptotic Pathways.
Topics: Acetylcholinesterase; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; | 2022 |
Antidepressant-Like Effects of Edaravone and Minocycline: Investigation of Oxidative Stress, Neuroinflammation, Neurotrophic, and Apoptotic Pathways.
Topics: Acetylcholinesterase; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; | 2022 |
Antidepressant-Like Effects of Edaravone and Minocycline: Investigation of Oxidative Stress, Neuroinflammation, Neurotrophic, and Apoptotic Pathways.
Topics: Acetylcholinesterase; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; | 2022 |
Antidepressant-Like Effects of Edaravone and Minocycline: Investigation of Oxidative Stress, Neuroinflammation, Neurotrophic, and Apoptotic Pathways.
Topics: Acetylcholinesterase; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; | 2022 |
Experimental Treatment with Edaravone in a Mouse Model of Spinocerebellar Ataxia 1.
Topics: Animals; Bayes Theorem; Cerebellum; Cognitive Dysfunction; Disease Models, Animal; Edaravone; Mice; | 2023 |
Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters.
Topics: Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Donepezil; Edaravone; Inflammation | 2023 |
Neuroprotective effect and possible mechanism of edaravone in rat models of spinal cord injury: a protocol for a systematic review and meta-analysis.
Topics: Animals; Bayes Theorem; Disease Models, Animal; Edaravone; Humans; Meta-Analysis as Topic; Neuroprot | 2023 |
Clinical and Pathological Benefits of Edaravone for Alzheimer's Disease with Chronic Cerebral Hypoperfusion in a Novel Mouse Model.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Disease Models, Animal; Edaravone; Male; Mice; Mice, Tra | 2019 |
Chronic cerebral hypoperfusion alters amyloid-β transport related proteins in the cortical blood vessels of Alzheimer's disease model mouse.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blood-Brain Barri | 2019 |
Edaravone attenuates lung injury in a hind limb ischemia-reperfusion rat model: A histological, immunohistochemical and biochemical study.
Topics: Animals; Biochemical Phenomena; Disease Models, Animal; Edaravone; Electron Transport Complex IV; Hi | 2020 |
Edaravone Administration Confers Neuroprotection after Experimental Intracerebral Hemorrhage in Rats via NLRP3 Suppression.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Brain; Caspase 1; Cerebral Hemorrhage; Disease | 2020 |
Effects of Edaravone on Nitric Oxide, Hydroxyl Radicals and Neuronal Nitric Oxide Synthase During Cerebral Ischemia and Reperfusion in Mice.
Topics: Animals; Brain; Brain Ischemia; Disease Models, Animal; Edaravone; Free Radical Scavengers; Hydroxyl | 2020 |
Edaravone protects from memory impairment induced by chronic L-methionine administration.
Topics: Animals; Antioxidants; Dementia, Vascular; Disease Models, Animal; Edaravone; Free Radical Scavenger | 2020 |
Edaravone Ameliorates Renal Warm Ischemia-Reperfusion Injury by Downregulating Endoplasmic Reticulum Stress in a Rat Resuscitation Model.
Topics: Animals; Apoptosis; Cardiopulmonary Resuscitation; Disease Models, Animal; Down-Regulation; Edaravon | 2020 |
Evaluation of the protective effect of edaravone on doxorubicin nephrotoxicity by [
Topics: Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Doxorubicin; Edaravone | 2020 |
Edaravone inhibits procaspase-3 denitrosylation and activation through FasL-Trx2 pathway in KA-induced seizure.
Topics: Animals; Caspase 3; Disease Models, Animal; Edaravone; Fas Ligand Protein; Kainic Acid; Male; Neurop | 2020 |
Oxidative stress evaluation of skeletal muscle in ischemia-reperfusion injury using enhanced magnetic resonance imaging.
Topics: Animals; Disease Models, Animal; Edaravone; Free Radical Scavengers; Magnetic Resonance Imaging; Mal | 2020 |
Protective effects of combined treatment with mild hypothermia and edaravone against cerebral ischemia/reperfusion injury via oxidative stress and Nrf2 pathway regulation.
Topics: Animals; Brain Ischemia; CA1 Region, Hippocampal; Combined Modality Therapy; Disease Models, Animal; | 2020 |
Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Edaravone; Exosomes; Infarction, Middle Cerebral Ar | 2020 |
Protective effects of edaravone on white matter pathology in a novel mouse model of Alzheimer's disease with chronic cerebral hypoperfusion.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Disease Models, Animal; Edaravone; Male; Mice; Neuroprot | 2021 |
Intravenous Edaravone plus Therapeutic Hypothermia Offers Limited Neuroprotection in the Hypoxic-Ischaemic Newborn Piglet.
Topics: Animals; Animals, Newborn; Brain; Disease Models, Animal; Edaravone; Hypothermia, Induced; Hypoxia; | 2020 |
Protective effect of edaravone against radiation-induced ovarian injury: a histopathological and immunohistochemical evaluation in an experimental rat model.
Topics: Animals; Disease Models, Animal; Edaravone; Female; Free Radical Scavengers; Ovary; Radiation Injuri | 2021 |
Anticonvulsive effects of edaravone on penicillin-induced focal onset seizure model in the conscious rats.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Edaravone; Injec | 2021 |
Effect of edaravone on pregnant mice and their developing fetuses subjected to placental ischemia.
Topics: Animals; Disease Models, Animal; Edaravone; Female; Ischemia; Male; Mice; Mice, Inbred C57BL; Oxidat | 2021 |
NADPH is superior to NADH or edaravone in ameliorating metabolic disturbance and brain injury in ischemic stroke.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Edaravone; Infarction, Middle Cer | 2022 |
Evaluation of Edaravone effects on the differentiation of human adipose derived stem cells into oligodendrocyte cells in multiple sclerosis disease in rats.
Topics: Adipose Tissue; Animals; Cell Differentiation; Disease Models, Animal; Drug Evaluation, Preclinical; | 2021 |
Establishing a high throughput drug screening system for cerebral ischemia using zebrafish larvae.
Topics: Animals; Brain; Brain Ischemia; Cell Death; Disease Models, Animal; Dizocilpine Maleate; Drug Evalua | 2021 |
Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma.
Topics: Animals; Antipyrine; Apoptosis; Disease Models, Animal; Edaravone; Electroretinography; Excitatory A | 2017 |
Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model.
Topics: Animals; Antipyrine; Apoptosis; Disease Models, Animal; Edaravone; Fibroblasts; Humans; Induced Plur | 2017 |
Edaravone and Its Protective Effects against Disease Progression in Neurological Conditions Besides Strokes.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Edaravone; Humans; | 2017 |
Edaravone Prevents Retinal Degeneration in Adult Mice Following Optic Nerve Injury.
Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Free Radical Scavengers; Immunohistochemistr | 2017 |
Edaravone attenuates oxidative stress induced by chronic cerebral hypoperfusion injury: role of ERK/Nrf2/HO-1 signaling pathway.
Topics: Animals; Antipyrine; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; Edara | 2018 |
Free radical scavenger edaravone produces robust neuroprotection in a rat model of spinal cord injury.
Topics: 3,4-Methylenedioxyamphetamine; Analysis of Variance; Animals; Antipyrine; Cytokines; Disease Models, | 2018 |
Edaravone attenuates neuronal apoptosis in hypoxic-ischemic brain damage rat model via suppression of TRAIL signaling pathway.
Topics: Animals; Animals, Newborn; Apoptosis; Cognitive Dysfunction; Disease Models, Animal; Edaravone; Gene | 2018 |
Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model.
Topics: Administration, Oral; Alzheimer Disease; Animals; Cell Line, Tumor; Disease Models, Animal; Dose-Res | 2018 |
Edaravone acts as a potential therapeutic drug against pentylenetetrazole-induced epilepsy in male albino rats by downregulating cyclooxygenase-II.
Topics: Animals; Antioxidants; Brain; Convulsants; Cyclooxygenase 2; Disease Models, Animal; Down-Regulation | 2019 |
The Role of Oxidative Stress in Microvascular Disturbances after Experimental Subarachnoid Hemorrhage.
Topics: Animals; Antioxidants; Blood-Brain Barrier; Brain; Brain Edema; Brain Injuries; Disease Models, Anim | 2019 |
Edaravone reduces Aβ-induced oxidative damage in SH-SY5Y cells by activating the Nrf2/ARE signaling pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidant Response Elements; Apoptosis; Cell Li | 2019 |
Edaravone prevents memory impairment in an animal model of post-traumatic distress.
Topics: Animals; Antioxidants; Apoptosis; Disease Models, Animal; Edaravone; Free Radical Scavengers; Male; | 2019 |
Effects of edaravone on pancreatic and renal injury in rats with severe acute pancreatitis.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Disease Models, Animal; Edaravone; Extracellular Si | 2020 |
Beneficial effects of edaravone in experimental model of amitriptyline-induced cardiotoxicity in rats.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Cardiotonic Agents; Cardiotoxicity; Diseas | 2019 |
Edaravone presents antidepressant-like activity in corticosterone model of depression in mice with possible role of Fkbp5, Comt, Adora1 and Slc6a15 genes.
Topics: Amino Acid Transport Systems, Neutral; Animals; Antidepressive Agents; Behavior, Animal; Catechol O- | 2019 |
Edaravone increases regional cerebral blood flow after traumatic brain injury in mice.
Topics: Animals; Antipyrine; Brain; Brain Injuries; Cerebrovascular Circulation; Disease Models, Animal; Eda | 2013 |
Therapeutic time window for edaravone treatment of traumatic brain injury in mice.
Topics: Animals; Antipyrine; Brain Injuries; Disease Models, Animal; Edaravone; Free Radical Scavengers; Jap | 2013 |
In vivo optical imaging correlates with improvement of cerebral ischemia treated by intravenous bone marrow stromal cells (BMSCs) and edaravone.
Topics: Animals; Antipyrine; Bone Marrow Cells; Bone Marrow Transplantation; Brain; Brain Ischemia; Disease | 2013 |
Oxidative stress interferes with white matter renewal after prolonged cerebral hypoperfusion in mice.
Topics: Animals; Antipyrine; Brain Ischemia; Disease Models, Animal; Edaravone; Free Radical Scavengers; Mic | 2013 |
Role of nitric oxide in the onset of facial nerve palsy by HSV-1 infection.
Topics: Animals; Antipyrine; Bell Palsy; Biomarkers; Disease Models, Animal; Edaravone; Facial Nerve; Facial | 2013 |
[Pharmacological postconditioning with lactic acid and low dose edaravone could attenuate myocardial reperfusion injury through mitochondrial pathway].
Topics: Animals; Antipyrine; Apoptosis; Cytochromes c; Disease Models, Animal; Edaravone; Ischemic Postcondi | 2013 |
Altered gene expression in an embolic stroke model after thrombolysis with tissue plasminogen activator and Stachybotrys microspora triprenyl phenol-7.
Topics: Animals; Antioxidants; Antipyrine; Benzopyrans; Calgranulin A; Disease Models, Animal; Edaravone; Fr | 2014 |
Inhibitory effects of edaravone in β-amyloid-induced neurotoxicity in rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antipyrine; CA1 Region, Hippocampal; Disease Mode | 2014 |
Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke.
Topics: Animals; Antipyrine; Cell Hypoxia; Disease Models, Animal; Drug Synergism; Edaravone; Humans; Hypoxi | 2014 |
Pericyte protection by edaravone after tissue plasminogen activator treatment in rat cerebral ischemia.
Topics: Acetylglucosamine; Animals; Antipyrine; Astrocytes; Brain Ischemia; Cell Proliferation; Disease Mode | 2014 |
Teriravone induces neurotoxicity in beagle dogs.
Topics: Animals; Antipyrine; Calcium-Binding Proteins; Cell Adhesion Molecules, Neuronal; Disease Models, An | 2014 |
The synergetic effect of edaravone and borneol in the rat model of ischemic stroke.
Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Brain; Brain Ischemia; Camphanes; Cell Survival; Cell | 2014 |
Pre- and posttreatment with edaravone protects CA1 hippocampus and enhances neurogenesis in the subgranular zone of dentate gyrus after transient global cerebral ischemia in rats.
Topics: Animals; Animals, Newborn; Antipyrine; Apoptosis; CA1 Region, Hippocampal; Cell Death; Cells, Cultur | 2014 |
Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia.
Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Apigenin; Brain; Brain Ischemia; Cell Count; Cell Lin | 2014 |
Compound IMM-H004, a novel coumarin derivative, protects against CA1 cell loss and spatial learning impairments resulting from transient global ischemia.
Topics: Animals; Antipyrine; bcl-2-Associated X Protein; Brain Ischemia; CA1 Region, Hippocampal; Caspase 3; | 2015 |
Protective effects of edaravone combined puerarin on inhalation lung injury induced by black gunpowder smog.
Topics: Animals; Antipyrine; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Drug Therapy, Combination | 2015 |
A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion.
Topics: Acetylglucosamine; Acute-Phase Proteins; Animals; Antipyrine; Creatinine; Disease Models, Animal; Ed | 2015 |
Edaravone protects rats against oxidative stress and apoptosis in experimentally induced myocardial infarction: Biochemical and ultrastructural evidence.
Topics: Animals; Antioxidants; Antipyrine; Apoptosis; C-Reactive Protein; Caspase 3; Creatine Kinase, MB For | 2015 |
The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model.
Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Fibrinolysis; Fibrinolytic Agents; Free Radi | 2015 |
Edaravone injection ameliorates cognitive deficits in rat model of Alzheimer's disease.
Topics: Acetylcholinesterase; Aldehydes; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antipyrine; Chol | 2015 |
Discovery of 3-n-butyl-2,3-dihydro-1H-isoindol-1-one as a potential anti-ischemic stroke agent.
Topics: Animals; Antioxidants; Antipyrine; Behavior, Animal; Benzofurans; Biological Availability; Brain; Ca | 2015 |
Protective effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced acute kidney injury in a rat model of sepsis.
Topics: Acute Kidney Injury; Animals; Antipyrine; Apoptosis; Blood Urea Nitrogen; Catalase; Cells, Cultured; | 2015 |
Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Astrocytes; Disease Models, Animal; Disease Prog | 2015 |
Edaravone abrogates LPS-induced behavioral anomalies, neuroinflammation and PARP-1.
Topics: Adaptation, Ocular; Animals; Antipyrine; Anxiety; Catalase; Disease Models, Animal; Dose-Response Re | 2016 |
[Effect of edaravone on oxidative stress and myocardial fibrosis induced by isoproterenol in rats].
Topics: Animals; Antipyrine; Cardiomyopathies; Collagen; Disease Models, Animal; Drugs, Chinese Herbal; Edar | 2015 |
Edaravone is a free radical scavenger that protects against laser-induced choroidal neovascularization in mice and common marmosets.
Topics: Animals; Antipyrine; Callithrix; Cell Proliferation; Cells, Cultured; Choroid; Choroidal Neovascular | 2016 |
Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model.
Topics: Animals; Antipyrine; Apoptosis; Cell Movement; Cells, Cultured; Cytokines; Disease Models, Animal; E | 2016 |
Protective Effects of Edaravone in Adult Rats with Surgery and Lipopolysaccharide Administration-Induced Cognitive Function Impairment.
Topics: Animals; Antipyrine; Brain; Cognitive Dysfunction; Cytokines; Disease Models, Animal; Edaravone; Fre | 2016 |
Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model.
Topics: Animals; Antipyrine; Bone Marrow Cells; Brain Ischemia; Chemokine CXCL12; Disease Models, Animal; Ed | 2016 |
Early Combined Therapy with Pharmacologically Induced Hypothermia and Edaravone Exerts Neuroprotective Effects in a Rat Model of Intracerebral Hemorrhage.
Topics: Animals; Antipyrine; Apoptosis Regulatory Proteins; Blood-Brain Barrier; Blotting, Western; Brain Ed | 2015 |
Stereotactic Administration of Edaravone Ameliorates Collagenase-Induced Intracerebral Hemorrhage in Rat.
Topics: Animals; Antipyrine; Apoptosis; Blood-Brain Barrier; Brain Edema; Cerebral Hemorrhage; Collagenases; | 2016 |
Edaravone improves survival and neurological outcomes after CPR in a ventricular fibrillation model of rats.
Topics: Animals; Antipyrine; Brain Injuries; Cardiopulmonary Resuscitation; Disease Models, Animal; Edaravon | 2016 |
The effects of edaravone in ketamine-induced model of mania in rats.
Topics: Analysis of Variance; Animals; Antimanic Agents; Antipyrine; Bipolar Disorder; Brain; Catalase; Dise | 2016 |
Edaravone injection reverses learning and memory deficits in a rat model of vascular dementia.
Topics: Animals; Antipyrine; Dementia, Vascular; Disease Models, Animal; Edaravone; Fear; L-Lactate Dehydrog | 2017 |
Edaravone reduces astrogliosis and apoptosis in young rats with kaolin-induced hydrocephalus.
Topics: Animals; Antidiarrheals; Antipyrine; Apoptosis; Body Weight; Caspase 3; Disease Models, Animal; Edar | 2017 |
Edaravone enhances the viability of ischemia/reperfusion flaps.
Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Graft Survival; Ischemic Preconditioning; Ma | 2017 |
Edaravone improves the survival of rats subjected to hemorrhagic shock without resuscitation.
Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Free Radical Scavengers; Male; Rats; Rats, S | 2008 |
Combination effects of normobaric hyperoxia and edaravone on focal cerebral ischemia-induced neuronal damage in mice.
Topics: Animals; Antipyrine; Blood Pressure; Cell Death; Cerebral Infarction; Disease Models, Animal; Edarav | 2008 |
Edaravone, a free radical scavenger, ameliorates experimental autoimmune encephalomyelitis.
Topics: Animals; Antipyrine; Calcium-Binding Proteins; CD3 Complex; Cell Line, Transformed; Disease Models, | 2008 |
Neuroprotective effects of edaravone, a free radical scavenger, on the rat hippocampus after pilocarpine-induced status epilepticus.
Topics: Animals; Antipyrine; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug; Edaravone | 2009 |
Preventive effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced lung injury in mice.
Topics: Acute Lung Injury; Animals; Antipyrine; Cell Line; Chemokine CXCL2; Disease Models, Animal; Edaravon | 2008 |
The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator.
Topics: Animals; Antipyrine; Behavior, Animal; Carotid Artery Thrombosis; Disease Models, Animal; Dose-Respo | 2009 |
Pretreatment with edaravone reduces lung mitochondrial damage in an infant rabbit ischemia-reperfusion model.
Topics: Acute Lung Injury; Animals; Animals, Suckling; Antipyrine; Constriction; Disease Models, Animal; Eda | 2008 |
Edaravone attenuates ischemia-reperfusion injury by inhibiting oxidative stress in a canine lung transplantation model.
Topics: Animals; Antipyrine; Disease Models, Animal; Dogs; Edaravone; Lipid Peroxidation; Lung; Lung Transpl | 2008 |
Correlation of free radical level and apoptosis after intracerebral hemorrhage in rats.
Topics: Analysis of Variance; Animals; Antipyrine; Apoptosis; Cerebral Hemorrhage; Disease Models, Animal; D | 2008 |
[Cardioprotective effect of edaravone pharmacological postconditioning on acute myocardial ischemia/reperfusion injury: experiment with rats].
Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Free Radical Scavengers; Male; Myocardial Re | 2008 |
Edaravone, a free radical scavenger, protects against retinal damage in vitro and in vivo.
Topics: Animals; Antipyrine; Cell Line; Cell Survival; Culture Media; Disease Models, Animal; Dose-Response | 2009 |
Edaravone prevents bowel infarction after acute superior mesenteric artery thromboembolism using autologous fibrin clots in a rabbit model.
Topics: Animals; Anticoagulants; Antipyrine; Case-Control Studies; Disease Models, Animal; Edaravone; Fibrin | 2009 |
Edaravone inhibits DNA peroxidation and neuronal cell death in neonatal hypoxic-ischemic encephalopathy model rat.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Animals, Newborn; Antipyrine; Cell Death; Deoxyguanosine; Dise | 2009 |
Edaravone in ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Clinical Trials as Topic; Disease Models, Animal | 2009 |
Edaravone reduces brain oedema and attenuates cell death after intracerebral haemorrhage in mice.
Topics: Animals; Antipyrine; Brain; Brain Edema; Cell Death; Cerebral Hemorrhage; Collagenases; Disease Mode | 2009 |
Development of cardiac dysfunction induced by repetitive transient myocardial ischemia is inhibited by edaravone in conscious rats.
Topics: Animals; Antipyrine; Consciousness; Disease Models, Animal; Edaravone; Free Radical Scavengers; Hype | 2009 |
Does the concomitant intra-arterial injection of asialoerythropoietin and edaravone mitigate ischaemic mucosal damage after acute superior mesenteric artery thromboembolism in a rabbit autologous fibrin clot model?
Topics: Animals; Antipyrine; Asialoglycoproteins; Catheterization; Disease Models, Animal; Drug Combinations | 2010 |
[Effects of edaravone on IRE1 mRNA expression and neuronal apoptosis in the hippocampus of rats with status convulsivus].
Topics: Animals; Antipyrine; Apoptosis; Disease Models, Animal; Edaravone; Hippocampus; In Situ Nick-End Lab | 2009 |
The novel free radical scavenger, edaravone, increases neural stem cell number around the area of damage following rat traumatic brain injury.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult Stem Cells; Aldehydes; Animals; Antipyrine; Behavior, Animal; Bra | 2009 |
Poly(ADP-ribose) polymerase-1 modulation of in vivo response of brain hypoxia-inducible factor-1 to hypoxia/reoxygenation is mediated by nitric oxide and factor inhibiting HIF.
Topics: Analysis of Variance; Animals; Antipyrine; Brain; Disease Models, Animal; Edaravone; Enzyme Inhibito | 2009 |
Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4.
Topics: Animals; Antipyrine; Aquaporin 4; Brain Edema; Brain Ischemia; Disease Models, Animal; Edaravone; Fr | 2009 |
Protective effects of the free radical scavenger edaravone on acute pancreatitis-associated lung injury.
Topics: Acute Lung Injury; Animals; Antipyrine; Disease Models, Animal; Edaravone; Free Radical Scavengers; | 2010 |
[The protective effect of edaravone on the treatment of sepsis in rats].
Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Free Radical Scavengers; Lung; Random Alloca | 2009 |
Gene network analysis to determine the effects of antioxidant treatment in a rat model of neonatal hypoxic-ischemic encephalopathy.
Topics: Animals; Animals, Newborn; Antioxidants; Antipyrine; Disease Models, Animal; Edaravone; Female; Free | 2010 |
[A comparative study on the protection effect of nerve growth factor and edaravone pretreatment against cerebral ischemia/reperfusion injury].
Topics: Animals; Animals, Newborn; Antipyrine; Apoptosis; Brain Ischemia; Cells, Cultured; Disease Models, A | 2010 |
[Effect of edaravone on extracellular signal-regulated kinase 1/2 pathway following severe traumatic brain injury in rats].
Topics: Animals; Antipyrine; Apoptosis; Brain Injuries; Disease Models, Animal; Edaravone; Male; Mitogen-Act | 2010 |
A novel rodent model of reperfusion injury following occlusion of the middle cerebral artery.
Topics: Animals; Antipyrine; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship | 2010 |
The antioxidant edaravone attenuates ER-stress-mediated cardiac apoptosis and dysfunction in rats with autoimmune myocarditis.
Topics: Animals; Antioxidants; Antipyrine; Apoptosis; Autoimmune Diseases; Disease Models, Animal; Down-Regu | 2010 |
Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage.
Topics: Acetylglucosamine; Animals; Antipyrine; Blood-Brain Barrier; Brain Injuries; Cerebral Cortex; Collag | 2010 |
Effect of a free radical scavenger, edaravone, on free radical reactions: related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model.
Topics: Animals; Antipyrine; Basilar Artery; Disease Models, Animal; Edaravone; Free Radical Scavengers; Gen | 2011 |
Effects of continuous intravenous infusion of MCI-186 on functional recovery after spinal cord injury in rats.
Topics: Animals; Antipyrine; Disease Models, Animal; Drug Administration Schedule; Edaravone; Free Radical S | 2011 |
Edaravone alleviates delayed neuronal death and long-dated cognitive dysfunction of hippocampus after transient focal ischemia in Wistar rat brains.
Topics: Animals; Antipyrine; Brain Ischemia; Cognition Disorders; Disease Models, Animal; Edaravone; Free Ra | 2011 |
Effects of edaravone on a rat model of punch-drunk syndrome.
Topics: Animals; Antipyrine; Athletic Injuries; Avoidance Learning; Boxing; Brain Concussion; Brain Injury, | 2011 |
Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Disease Models, Animal; Edaravone; Feasibility S | 2011 |
Edaravone, an ROS scavenger, ameliorates photoreceptor cell death after experimental retinal detachment.
Topics: Aldehydes; Animals; Antipyrine; Blotting, Western; Caspases; Cell Survival; Disease Models, Animal; | 2011 |
C/EBP homologous protein deficiency attenuates myocardial reperfusion injury by inhibiting myocardial apoptosis and inflammation.
Topics: Animals; Antipyrine; Apoptosis; Cells, Cultured; Chemokines; Cytokines; Disease Models, Animal; DNA- | 2011 |
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats.
Topics: Acetates; Administration, Oral; Animals; Antipyrine; Atrophy; Behavior, Animal; Brain Injury, Chroni | 2011 |
Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice.
Topics: Aldehydes; Animals; Antipyrine; Benzopyrans; Brain; Cerebral Infarction; Disease Models, Animal; Eda | 2011 |
The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis.
Topics: Animals; Antipyrine; Bleomycin; Disease Models, Animal; Edaravone; Fibrosis; Free Radical Scavengers | 2011 |
New method for absolute spinal cord ischemia protection in rabbits.
Topics: Animals; Antipyrine; Aorta; Biomarkers; Combined Modality Therapy; Constriction; Disease Models, Ani | 2011 |
Edaravone, a free radical scavenger, attenuates behavioral deficits following transient forebrain ischemia by inhibiting oxidative damage in gerbils.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Analysis of Variance; Animals; Antipyrine; Behavioral Symptoms; Deoxygu | 2012 |
Ligation of the pterygopalatine and external carotid arteries induces ischemic damage in the murine retina.
Topics: Animals; Antipyrine; Blood Flow Velocity; Carotid Artery, External; Cell Count; Cerebrovascular Circ | 2011 |
Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury.
Topics: Analysis of Variance; Animals; Antipyrine; Bromodeoxyuridine; Cerebral Infarction; Cerebral Ventricl | 2012 |
Protective effects of edaravone on experimental spinal cord injury in rats.
Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Free Radical Scavengers; Male; Methylprednis | 2011 |
Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antipyrine; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apop | 2012 |
Involvement of AMPK and MAPK signaling during the progression of experimental autoimmune myocarditis in rats and its blockade using a novel antioxidant.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antipyrine; Autoimmune Diseases; Disease Models, Anim | 2012 |
Perfluorocarbon-facilitated CNS oxygen toxicity in rats: reversal by edaravone.
Topics: Animals; Antipyrine; Brain; Catalase; Disease Models, Animal; Drug Synergism; Edaravone; Electroence | 2012 |
Edaravone inhibits apoptosis caused by ischemia/reperfusion injury in a porcine hepatectomy model.
Topics: Animals; Antipyrine; Apoptosis; Biomarkers; Cytoprotection; Disease Models, Animal; Edaravone; Free | 2012 |
Protective effects of MCI-186 on transplantation of bone marrow stromal cells in rat ischemic stroke model.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antipyrine; Brain; Brain Infarction; Brain-Derived | 2012 |
Reactive oxygen species and the MEK/ERK pathway are involved in the toxicity of clostridium perfringens α-toxin, a prototype bacterial phospholipase C.
Topics: Animals; Antipyrine; Bacterial Toxins; Calcium-Binding Proteins; Cell Line; Clostridium perfringens; | 2012 |
Effect of a free radical scavenger on nitric oxide release in microvessels.
Topics: Acetylcholine; Animals; Antipyrine; Aorta, Abdominal; Disease Models, Animal; Edaravone; Free Radica | 2013 |
Aminophylline, administered at usual doses for rodents in pharmacological studies, induces hippocampal neuronal cell injury under low tidal volume hypoxic conditions in guinea-pigs.
Topics: Aminophylline; Animals; Antipyrine; CA1 Region, Hippocampal; Creatine Kinase, BB Form; Disease Model | 2013 |
Myocardial protection of MCI-186 in rabbit ischemia-reperfusion.
Topics: Animals; Antipyrine; Blood Pressure; Disease Models, Animal; Edaravone; Electrocardiography; Free Ra | 2002 |
Contractile responses to reactive oxygen species in the canine basilar artery in vitro: selective inhibitory effect of MCI-186, a new hydroxyl radical scavenger.
Topics: Animals; Antipyrine; Basilar Artery; Disease Models, Animal; Dogs; Edaravone; Female; Free Radical S | 2002 |
Edaravone, a novel free radical scavenger, prevents liver injury and mortality in rats administered endotoxin.
Topics: Alanine Transaminase; Animals; Antipyrine; Chemokine CCL4; Chemokines; Chemokines, CC; Chemokines, C | 2003 |
MCI-186 prevents spinal cord damage and affects enzyme levels of nitric oxide synthase and Cu/Zn superoxide dismutase after transient ischemia in rabbits.
Topics: Animals; Antipyrine; Biopsy, Needle; Disease Models, Animal; Edaravone; Immunohistochemistry; Inject | 2003 |
Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain.
Topics: Aldehydes; Animals; Antipyrine; Brain Ischemia; Cell Count; Deoxyadenosines; Disease Models, Animal; | 2004 |
EPR imaging to estimate the in vivo intracerebral reducing ability of mature rats after neonatal hypoxic-ischemic brain injury.
Topics: Animals; Animals, Newborn; Antipyrine; Blood-Brain Barrier; Brain; Carotid Artery, Common; Cyclic N- | 2004 |
Intrathecal edaravone, a free radical scavenger, is effective on inflammatory-induced pain in rats.
Topics: Animals; Antipyrine; Behavior, Animal; Disease Models, Animal; Disinfectants; Dose-Response Relation | 2005 |
Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model.
Topics: Analysis of Variance; Animals; Antipyrine; Blood Vessels; Cerebral Hemorrhage; Disease Models, Anima | 2005 |
The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anti | 2005 |
The free radical scavengers edaravone and tempol suppress experimental dextran sulfate sodium-induced colitis in mice.
Topics: Animals; Antipyrine; Colitis; Cyclic N-Oxides; Dextran Sulfate; Disease Models, Animal; Edaravone; F | 2006 |
MCI-186 (edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A(2) in an isolated rat lung model after 18 h of cold preservation.
Topics: Animals; Antipyrine; Bronchoalveolar Lavage Fluid; Cold Ischemia; Disease Models, Animal; Edaravone; | 2006 |
Apoptosis in ischemic spinal cord injury.
Topics: Animals; Antipyrine; Apoptosis; Disease Models, Animal; Edaravone; Free Radical Scavengers; Humans; | 2006 |
Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis.
Topics: Aldehydes; Animals; Antipyrine; Apolipoproteins E; Apoptosis; Atherosclerosis; Cells, Cultured; Chol | 2007 |
Treatment with edaravone improves the survival rate in renal warm ischemia-reperfusion injury using rat model.
Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Free Radical Scavengers; Male; Rats; Rats, I | 2006 |
The therapeutic efficacy of edaravone in extensively burned rats.
Topics: Animals; Antipyrine; Burns; Disease Models, Animal; Edaravone; Free Radical Scavengers; Free Radical | 2006 |
Protective effect of radical scavenger edaravone against puromycin nephrosis.
Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Follow-Up Studies; Free Radical Scavengers; | 2006 |
Effect of prophylactically administered edaravone during antegrade cerebral perfusion in a canine model of old cerebral infarction.
Topics: Analysis of Variance; Animals; Antipyrine; Blood Chemical Analysis; Cardiopulmonary Bypass; Cerebral | 2007 |
Effects of edaravone in heart of aged rats after cerebral ischemia-reperfusion injury.
Topics: Aging; Animals; Antipyrine; Apoptosis; Blotting, Western; Brain Ischemia; Cell Survival; Disease Mod | 2007 |
Microcirculatory changes in experimental mesenteric longitudinal ulcers of the small intestine in rats.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Cytokines; Disease Models | 2007 |
Protective effect of edaravone against endolymphatic hydrops.
Topics: Animals; Antipyrine; Disease Models, Animal; Drug Administration Schedule; Edaravone; Endolymphatic | 2007 |
Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats.
Topics: Animals; Antipyrine; Death Domain Receptor Signaling Adaptor Proteins; Disease Models, Animal; DNA F | 2007 |
Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage.
Topics: Acute Disease; Animals; Antipyrine; Basal Ganglia; Brain Edema; Cerebral Cortex; Cerebral Hemorrhage | 2008 |
Edaravone prevents kainic acid-induced neuronal death.
Topics: Aldehydes; Animals; Antipyrine; Brain; Cell Death; Disease Models, Animal; Down-Regulation; Edaravon | 2008 |
Inhibition of neointimal hyperplasia development by MCI-186 is correlated with downregulation of nuclear factor-kappaB pathway.
Topics: Angioplasty, Balloon; Animals; Antioxidants; Antipyrine; Carotid Artery Diseases; Carotid Artery Inj | 2008 |
Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
Topics: Animals; Antipyrine; Brain; Brain Ischemia; Cerebral Arteries; Disease Models, Animal; Edaravone; Fr | 1997 |
Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat.
Topics: Animals; Antipyrine; Brain; Caudate Nucleus; Cerebral Infarction; Cyclic N-Oxides; Disease Models, A | 1999 |